WO2004108763A2 - Mutants of the factor vii epidermal growth factor domain - Google Patents

Mutants of the factor vii epidermal growth factor domain Download PDF

Info

Publication number
WO2004108763A2
WO2004108763A2 PCT/CA2004/000826 CA2004000826W WO2004108763A2 WO 2004108763 A2 WO2004108763 A2 WO 2004108763A2 CA 2004000826 W CA2004000826 W CA 2004000826W WO 2004108763 A2 WO2004108763 A2 WO 2004108763A2
Authority
WO
WIPO (PCT)
Prior art keywords
fvii
seq
fviia
modified
cell
Prior art date
Application number
PCT/CA2004/000826
Other languages
French (fr)
Other versions
WO2004108763A3 (en
Inventor
Morris Blajchman
Bryan Clarke
Original Assignee
Canadian Blood Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canadian Blood Services filed Critical Canadian Blood Services
Priority to CA002528239A priority Critical patent/CA2528239A1/en
Priority to EP04735858A priority patent/EP1636358A2/en
Publication of WO2004108763A2 publication Critical patent/WO2004108763A2/en
Publication of WO2004108763A3 publication Critical patent/WO2004108763A3/en
Priority to US11/294,670 priority patent/US20060234935A1/en
Priority to US11/636,030 priority patent/US20070207960A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to mutants of Factor VII in the epidermal growth factor-like domain.
  • the invention is further related to pharmaceutical compositions comprising such mutant factors and their uses .
  • Human factor VII is a 406 amino acid [1] single-chain 50 kDa glycoprotein essential for the initiation of the blood coagulation cascade, as described in United States Patent No. 5,580,560. FVII is synthesized in the liver and is secreted into the blood where it circulates predominately, approximately 98%, as an inactive zymogen precursor of activated factor VII
  • FVIIa the serine protease that plays a key role in the initiation of the blood coagulation cascade.
  • TF cell-surface receptor tissue factor
  • FVII to FVIIa involves the hydrolysis of a single peptide bond between Argl52 and Ilel53, thereby resulting in a two-chain molecule consisting of a light chain of 152 amino acids residues, and a heavy chain of 254 amino acid residues held together by a single disulfide bond.
  • FVII and FVIIa are multidomain proteins comprising an N-terminal Gla domain ( ⁇ -carboxyglutamic acid domain) , which confers the ability of FVII ' or FVIIa to. bind, in a reversible calcium-dependent manner to membranes containing negatively charged phospholipids, followed by two epidermal growth factor (EGF) -like domains, referred to as the EGF-1 and EGF-2, and a serine protease domain. These domains appear to be involved, to different extends, in an optimal interaction with TF.
  • GEF epidermal growth factor
  • Initiation of coagulation begins with the binding of either FVII or FVIIa to TF on the cell membrane. It is now well established that the first epidermal growth factor-like domain (EGF-1) of FVII is essential for the high affinity binding to TF [26, 15] . Analysis of the
  • FVIIa-sTF a complex of active site-inhibited human FVIIa with a protease-cleaved form of human soluble tissue factor (sTF) , crystal structure [19] has shown that 70% of the binding energy between the two molecules involved amino acid residues in the EGF1 domain of FVII, yet this domain comprises only 38 of the 406 amino acids of human FVII. It should also be noted that the FVII-TF interaction
  • variable activity of TF from various animal tissues in the initiation of coagulation has been known [18] . Accordingly, it has been shown that the FVII-TF interaction is species-specific. For example, FVII from rabbits and FVII from mice both exhibited dramatically increased enzymatic activity with human TF when compared with homologous TF [18] .
  • the FVII EGF-1 domain of FVII provides the region of greatest contact during the interaction of FVIIa with TF.
  • Leonard et al have shown that allosteric interactio (s) between the FVIIa active site (contained within the protease domain) and the EGF-1 domain is sensitive to variation in active site occupant structure, thereby indicating that the conformational change associated with FVII activation and active site occupation involves the EGF-1 domain [33] . Since the interaction of FVII with TF appears to play a critical role in coagulation, and other important biological processes, an understanding of the mechanisms by which the EGF-1 domain of FVII interacts with TF is of particular relevance and importance .
  • the present invention fulfills a great need in the present art.
  • Mutants of human rFVIIa with increased affinity for TF and/or clotting activity could make the current use of wild-type rFVIIa obsolete. Furthermore, enzymatically- inactive forms of high-affinity rFVIIa mutants for TF could become novel anticoagulants.
  • An aim of the present invention is to provide FVII/FVIIa mutants with enhanced biological activity, enzymatic activity and/or binding affinity for TF.
  • a preferred aim of the ' present invention is to provide human FVII/FVIIa mutants with enhanced biological activity, and more preferably, enhance'd enzymatic activity and/or affinity for TF.
  • the present invention provides modified FVII/FVIIa mutants with enhanced biological activity, enzymatic activity and/or binding affinity for TF via site-directed mutagenesis of selected amino acids.
  • the present invention provides a modified factor Vll/VIIa (also referred to herein as mutant FVII/FVIIa (or rFVII, rFVII, or rFVII/rFVIIa) , preferably human FVII/FVIIa, comprising one or more mutation(s), wherein the mutation (s) is/are in the epidermal growth factorlike (EGF-1) domain.
  • a modified factor Vll/VIIa also referred to herein as mutant FVII/FVIIa (or rFVII, rFVII, or rFVII/rFVIIa) , preferably human FVII/FVIIa, comprising one or more mutation(s), wherein the mutation (s) is/are in the epidermal growth factorlike (EGF-1) domain.
  • the present invention provides modified FVII/FVIIa comprising one or more mutation(s), wherein the mutation (s) is/are in the epidermal growth factor-like (EGF-1) domain, and in a preferred embodiment of the invention, the mutation (s) is/are at one, more than one, or all amino acid residues at residues 53, 62, 74, 75, 83, or any combination thereof, wherein the mutation may be to any amino acid residue that confers enhanced biological activity of FVII/FVIIa to, for example, positively improve blood coagulation, or increase affinity for TF.
  • the mutation may be to any amino acid residue that confers enhanced biological activity of FVII/FVIIa to, for example, positively improve blood coagulation, or increase affinity for TF.
  • a mutation embodied by the present invention may be mutant FVII (K62x) , wherein amino acid x is selected from any amino acid residue that increases the biological activity of FVII, such as the binding affinity of FVII for TF, or the clotting activity of FVII, or the amidolytic activity of FVII, or any functional activity that facilitates or improves the initiation of the blood coagulation cascade.
  • amino acid x is selected from any amino acid residue that increases the biological activity of FVII, such as the binding affinity of FVII for TF, or the clotting activity of FVII, or the amidolytic activity of FVII, or any functional activity that facilitates or improves the initiation of the blood coagulation cascade.
  • modified FVII/FVIIa mutants of the present invention comprise one, more than one or all mutations selected from (S53N) , (K62E) , (P74A) ,
  • a mutation embodied by the present invention may be mutant FVII (S53N) (K62E) , FV I(K62T), FVII (S53N) (K62T) , or FVII(K62E) (T83K) , or any combination of mutations FVII(S53N), FVII (K62E) , FVII (K62D) , FVII (K62N) ,
  • the modified FVII/FVIIa is FVII(K62E), where FVII(K62E) is a modified human FVII/FVIIa comprising a K to E mutation at amino acid residue 62.
  • the modified FVII/FVIIa is FVII (K62T) , where FVII (K62T) is a modified human FVII/FVIIa comprising a K to T mutation at amino acid residue 62.
  • Table 2 below provides some FVII mutants with enhanced coagulant activity.
  • the present invention also provides a modified polypeptide, immunogenic polypeptide, or polypeptide fragment comprising a modified FVII/FVIIa ' according to the present invention, wherein said modified FVII/FVIIa more specifically comprises mutations of the EGF-1 domain, and preferably mutations at one, more than one, or all amino acid residues at positions 53, 62, 74, 75, 83, or any combination thereof.
  • a modified FVII/FVIIa according to the present invention provides enhanced biological activity, and more specifically enhanced enzymatic activity and/or affinity for TF.
  • the present invention also provides nucleotide sequence of an isolated nucleotide sequence comprising a sequence that encodes a purified polypeptide, immunogenic polypeptide, or polypeptide fragment of a modified FVII/FVIIa according to the present invention, wherein said modified FVII/FVIIa ' more specifically comprises mutation (s) within the EGF-1 domain, or mutations at one, more than one, or all amino acid residues at positions 53, 62, 74, 75, 83, or any combination thereof.
  • the invention also comprises recombinant nucleotide, or isolated nucleotide sequences encoding modified FVII/FVIIa according to the present, wherein said modified FVII/FVIIa more specifically comprises mutation (s) within the EGF-1 domain, or mutations at one, more than one, or all amino acid residues at positions 53, 62, 74, 75, 83, or any combination thereof, or any degenerate variant thereof.
  • mutant FVII(P74A) may be encodes by different but equivalent nucleotide sequences wherein mutant amino.
  • acid A, Alanine may be encoded by different, codons, such as GCA or GCC.
  • primers directed towards the production of Ala may, comprise different Ala codons, and will yield equivalent amino acid products.
  • the nucleotide sequences of the present invention also comprise degenerate variants thereof.
  • the present invention comprises nucleotide sequence comprising a nucleotide sequence, for example, a cDNA or degenerate variant thereof, that encodes a modified FVII/FVIIa of the present invention, wherein said nucleotide sequence specifically hybridizes to a sequence selected from SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, or any degenerate variant thereof.
  • SEQ ID NO:l to SEQ ID NO 4 are mutagenic primers of a preferred embodiment of the invention, wherein the highlighted codon encodes the mutagenic amino acid, and where said primer sequences bind to complementary nucleotide sequences, such as cDNAs, encoding modified FVII/FVIIa according to the present invention.
  • the present invention also comprises mutagenic primers noted below, and any degenerate variants thereof, and additionally comprises nucleotide sequence and degenerate variants to the modified FVII/FVIIa that hybridized said mutagenic primer.
  • K62 ⁇ Q (5'-GGGCTCCTGCCAGGACCAGCTC-3') (SEQ ID NO: 25)
  • K62 ⁇ T (5'-GGGCTCCTGCACGGACCAGCTC-3') (SEQ ID NO:26)
  • P74 ⁇ A (5'-GCTTCTGCCTCGCTGCCTTCGAG-3') (SEQ ID NO:27)
  • A75 ⁇ D (5'-CTGCCTCCCTGACTTCGAGGGC-3' ) (SEQ ID NO:28)
  • K62 ⁇ X (5'-GGGCTCCTGCNNNGACCAGCTC-3') (SEQ ID NO: 30) , wherein NNN of SEQ ID NO: 30 is a codon that encodes any amino acid the improves the ' biological activity of FVII, through the modification of residue 62 of the EGF-1 domain of FVII.
  • the mutations effected, at each codon are:
  • LYSINE62 (5 ⁇ AG-3') TO THREONINE (5 ⁇ CG-3 1 LYSINE62 (5'AAG-3') TO THREONINE (5 ⁇ CG-3'
  • PROLINE74 (5*CCT-3') TO ALANINE (5'GCT-3'
  • ALANINE75 (5'GCC-3') TO ASPARTIC ACID (5'GAC-3'
  • THREONINE83 (5 ⁇ CG-3') TO LYSINE (5'AAA-3'
  • the present invention provides for any mutant FVII (K62x) , or any FVII mutant comprising a mutation at K62, wherein amino acid x is selected from any amino acid residue that increases the biological activity of FVII, such as the binding affinity of FVII for TF, or the clotting activity of FVII, or the amidolytic activity of FVII, or any functional activity that facilitates or improves the initiation of the blood coagulation cascade.
  • amino acid x is selected from any amino acid residue that increases the biological activity of FVII, such as the binding affinity of FVII for TF, or the clotting activity of FVII, or the amidolytic activity of FVII, or any functional activity that facilitates or improves the initiation of the blood coagulation cascade.
  • preferred embodiments of the present invention also comprise recombinant nucleotide sequences encoding modified FVII/FVIIa mutants according to the present invention, or any degenerate variant thereof, wherein said modified FVII/FVIIa more specifically comprises mutation (s) within the EGF-1 domain, or mutations at one, more than one, or all amino acid residues at positions 53, 62, 74, 75, 83, or any combination thereof.
  • the present invention also comprises corresponding nucleotide sequences encoding modified FVII/FVIIa mutants of the present invention and any degenerate variants thereof.
  • the Sequence listings provided for the nucleotide and amino acid sequences of the FVII/FVIIa mutants comprises the sequence of the EGF- 1 domain, however it is understood that the present invention embodies the functional full length FVII/FVIIa mutant, or- any functional fragment thereof, where the modified EGF-1 domain of said modified FVII/FVIIa mutant is provided herein.
  • the present invention provides: SEQ ID NO:l, SEQ ID NO 2, SEQ ID NO: 3 , SEQ ID NO:4 , SEQ ID NO:5, SEQ ID NO: 6, SEQ ID N0:7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, wherein SEQ ID NO: 1-10 refer to nucleotide sequences, wherein degenerate equivalents are also embodied, herein, of the EGF-1 domain of the mutant FVII (xABy) . Accordingly the present invention embodies any FVII mutant sequence comprising the nucleotide sequence of the EGF-1 domain comprising a sequence of any one of SEQ ID NO: 1-10 or any degenerate equivalent thereof.
  • the present invention also comprises any vector comprising the FVII mutant sequences embodied herein, wherein said vector may be an expression vector, preferably pCMV5, or a cloning vector, preferably pUCl9.
  • a culture cell, cell or cell line preferably HEK293, CHO or BHK cells or any related cell or progeny thereof, wherein said culture cell, cell or cell line is transfected with a FVII modified nucleotide sequences, wherein said- modified nucleotide sequences comprises a modified EGF-1 domain sequence of any one of SEQ ID NO: 1-10.
  • the present invention also provides SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO: 11, which correspond to the amino acid sequence of the modified EGF-1 domain comprises in the modified FVII/FVIIa (xABy) protein, or functional fragment thereof embodied herein, as provided by the nucleotide sequence of SEQ ID NO: 1-10. Accordingly the present invention embodies any FVII mutant sequence comprising the amino acid sequence of the EGF-1 domain comprising a sequence of any one of SEQ ID NO: 11-20 or any functional variant or equivalent thereof.
  • the present invention embodies the functional full length FVII/FVIIa mutant, or any functional fragment or equivalent thereof, where the modified EGF-1 domain of said modified FVII/FVIIa mutant is provided herein, as specified in SEQ ID NO: 11-20.
  • the modified modified FVII/FVIIa (xABy) of the present invention may be produced as full length or as biologically active functional fragments thereof, wherein the mutant protein or polypeptide embodied herein exhibits improved biological activity compared to the FVII/FVIIa wild type.
  • the modified FVII mutants embodied herein may be expressed, isolated- and purified according to known protein and polypeptide procedures .
  • mutagenic primers having SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, and SEQ ID NO:30, wherein SEQ ID NO:21-28 comprise mutagenic primers that hybridizes to the nucleotide sequences of SEQ ID NO: 1-10, respectively.
  • the present application provides modified FVII/FVIIa, or functional fragment thereof, comprising one or more mutation(s), wherein said mutation (s) are in the EGF-1 domain, and are preferably any any one, more than one, or all residues 53, 62, 74, 75, or 83 of the EGF-1 of FVII/FVIIa, provided that said mutation as residues 53, 62, 74, 75, or 83 results in a modified FVII/FVIIa having improved biological activity with respect to the wild type FVII. More preferably, the modified FVII mutant comprises a mutation at K62 of the EGF-1 domain, wherein the mutation at K62 confers enhanced biological activity-.
  • a modified FVII/FVIIa protein or biologically active fragment thereof, wherein the modified FVII/FVIIa comprises mutation (s) at any one of residues 53, 62, 74, 75, or 83 of the EGF-1, or any combination thereof.
  • the present invention provides a modified FVII/FVIIa (K62x) protein, or biologically active fragment thereof, and more preferably a modified ⁇ FVII/FVIIa (K62E) protein or functional equivalent thereof.
  • the present invention also comprises any degenerate variants of the nucleotide sequences according to the present invention.
  • the present invention also comprises cDNA nucleotide sequences and degenerate variants, that encode modified FVII/FVIIa, wherein said modified FVII/FVIIa more specifically comprises mutation (s) within the EGF-1 domain, or mutations at one, more than one, or all amino acid residues at positions 53, 62, 74, 75, 83, or any combination thereof.
  • the present invention comprises a nucleotide sequence comprising any one of SEQ ID NO: 1-10, or any nucleotide sequence that comprises a sequence (s) encoding one, more than one, or all mutations at residues 53, 62, 74, 75, 83 of the EGFl domain of FVII/FVIIa, or any combination thereof, or any degenerate variant thereof, that yields a modified FVII/FVIIa according to the present invention.
  • the present invention additionally comprises a nucleotide sequence, such as a cDNA, that encodes for a modified FVII/FVIIa mutant comprising mutation (s) at one, more than one, or all ⁇ amino acid residues at positions 53, 62, 74, 75, 83, of human FVII/FVIIa, or any combination thereof.
  • a nucleotide sequence such as a cDNA
  • the present invention comprises nucleotide sequence that encodes a polypeptide with the amino acid sequence of Fig.l, or a polypeptide comprising any single or individual mutation contained therein, or any multiple mutations, or any combinations thereof.
  • the present invention also provides a vector comprising a nucleotide sequence encoding a modified FVII/FVIIa according to the present invention, and more specifically, a wherein said modified FVII/FVIIa more specifically comprises mutation (s) within the EGF-1 domain, or mutations at one, more than one, or all amino acid residues at positions 53, 62, 74, 75, 83, or any combination thereof.
  • the present invention also provides vectors comprising all the ' various nucleotide sequences of the present invention, wherein said nucleotide sequences encode a modified FVII/FVIIa according to the present invention, or equivalents thereof, such as protein fragments, or (poly) peptides, or other equivalent functional molecules.
  • a vector of the present invention may be an expression vector, preferably pCMV5, or, a cloning vector, preferably pUCl9.
  • a culture cell or cell line transfected with a vector Recording to the present invention, or a progeny of said cell, wherein said culture cell or cell line, preferably HEK293, CHO, or BHK cells, or any other cell of human or non human origin suitable for the expression of a modified FVII/FVIIa of the present invention, or for the pharmaceutical, clinical or therapeutic uses thereof, wherein said cell or cell line is capable of expressing modified FVII/FVIIa according to the present invention or functional equivalents thereof.
  • said culture cell or cell line preferably HEK293, CHO, or BHK cells, or any other cell of human or non human origin suitable for the expression of a modified FVII/FVIIa of the present invention, or for the pharmaceutical, clinical or therapeutic uses thereof, wherein said cell or cell line is capable of expressing modified FVII/FVIIa according to the present invention or functional equivalents thereof.
  • the present invention also provides a culture cell or cell line that permanently expresses a mutant or modified nucleotide sequence of a modified FVII/FVIIa according to the present invention, wherein said culture cell or cell line is transfected with a vector according to the present invention and, may be preferably co- transfected with a selection plasmid, such as pSV2neo.
  • a selection plasmid such as pSV2neo.
  • the present invention provides a culture cell or cell line that expresses a modified FVII/FVIIa according to the present invention, wherein the cell is preferably HEK293, CHO, or BHK cells, or any other cell of human or non human origin suitable for the expression of a modified FVII/FVIIa of the present invention, or for the pharmaceutical, clinical or therapeutic uses thereof, wherein said cell or cell line is capable of expressing modified FVII/FVIIa according to the present invention or functional equivalents thereof.
  • the present invention also provides a cell, or cell line comprising the recombinant nucleotide molecule encoding a mutant FVII according to the present invention.
  • the present invention provides a cultured cell, or cell line comprising a vector according to the present invention, wherein said culture cell or cell line is preferably HEK293, CHO or BHK CELLS.
  • the present invention also comprises HEK293 cell lines which permanently express recombinant FVII/FVIIa mutants.
  • the mutant nucleotide sequences, or cDNAs, of mutants FVII(K62E), and/or FVII (A75D) , or other modified FVII/FVIIa of the present invention were subcloned into an expression vector, preferably pCMV5 expression vector and co-transfected into a cell, preferably HEK293 cell line along with a selection plasmid, preferably pSV2neo.
  • an expression vector preferably pCMV5 expression vector
  • a selection plasmid preferably pSV2neo.
  • human FVII mutants "* wherein mutations considered are, in the EGF-1 domain, and more specifically at positions 53, 62, 74, 75, 83, or any combination thereof, wherein residues S53, K62, P74, A75, T83 may be mutated to any amino acid residue that increases the biological activity of FVII/FVIIa and preferably modified human FVII/FVIIa, to positively improve blood coagulation.
  • a modified or mutant protein factor, or equivalent thereof wherein said protein factor is human FVII/FVIIa, and where at least one amino acid in the EGF- 1 domain.
  • a modified or mutant protein factor, or equivalent thereof comprises mutation (s) preferably at residue positions 53, 62, 74, 75, 83, has - been substituted with another amino acid which confers increased functional activity, such as binding affinity to TF, or clotting affinity, to said mutant factor.
  • one, more or all the amino acid residues at S53, K62, P74, A75, T83 have been mutated to FVII(S53N), FVII(K62E), FVII (K62D) , FVII(K62N), FVII (K62Q) , FVII (K62T) , FVII (P74A) , FVII(A75D), FVII(T83K), or any combination thereof.
  • the present invention is contemplated to cover any combination of mutations at any amino acid residue comprised in the EGF-1 domain, , and more preferably at residues S53, K62, P74, A75, T83 of human FVII/FVIIa.
  • the invention is further directed to a method of expressing a modified factor Vll/VIIa according to the present invention or equivalent thereof, in a cell, preferably cell line HEK293, wherein the method comprises: providing an expression vector, preferably pCMV5, encoding the modified protein; introducing the vector into the cell; and maintaining the cell under conditions permitting the expression of the protein in the cell .
  • the method of the present invention also provides for the expression of the modified FVII/FVIIa in vivo or in vitro in other permanent cell lines.
  • the present invention provides mutant human FVII(K62E), wherein the mutant factor exhibits significantly increased clotting activity when compared to plasma- derived human FVII/FVIIa.
  • Combinations of other FVII mutants according to the invention, such as FVII (K62E) , , and FVII (A75D) aim to further increase the 'biological .activity of the FVII, and preferably of human FVII.
  • the present invention also- comprises a cell transformed with a recombinant nucleotide molecule comprising an isolated nucleotide sequence, and degenerate variants thereof, encoding a mutant or modified FVII protein or equivalent thereof, wherein said i mutations are at one or more than one residue of the EGF-
  • Mutant FVIIa can be obtained by activating mutant FVII.
  • an expression vector and a cloning vector encoding modified human FVII cDNA wherein said expression vector is preferably pCMV5 or another suitable expression vector, said cloning vector is preferably pUC19 or another suitable expression vector, and wherein said cDNA is nucleotide sequence encoding a modified FVII/FVIIa, and preferably a modified human FVII/FVIIa, wherein the mutation to FVII may be any mutation according to the present invention. More specifically, said mutation- may be at any amino acid comprising the EGF-1 domain of FVII, and preferably at any one of, more than one, or all amino acid residues 53, 62, 74, 75 and 83 or any combination thereof.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a modified FVII/FVIIa mutant product, or equivalent thereof, such as a functional peptide fragment, or other fragment, according to the present invention, or complexes of said modified FVII/FVIIa and a pharmaceutically accepted carrier.
  • the present invention further provides a method of treating a patient with condition or disorder, such as a bleeding disorder, or treating patients with thrombocytopenia, wherein the method comprises introducing into the patient a pharmaceutically effective amount of a modified FVII/FVIIa, and preferably a modified human FVII/FVIIa according to the invention, or any functional equivalent thereof, or an expression vector encoding a modified human FVII protein, such that an amount of the modified protein is effective to improve blood coagulation.
  • a modified human FVII with increased binding affinity for TF or a modified human FVII-TF complex, wherein the . amounts of the modified FVII protein, or the complexed modified FVII are in amounts effective to improve blood coagulation.
  • the present invention provides a method of treating a patient, preferably a patient with a bleeding condition or other blood related condition, such as patients with thrombocytopenia or other conditions, where said method comprises administration of a pharmaceutically effective amount of a modified FVII/FVIIa according to the invention, wherein said modified FVII/FVIIa more specifically comprises mutation (s) within the EGF-1 domain, or mutations at one, more than one, or all amino acid residues at positions 53, 62, 74, 75, 83, or any combination thereof.
  • the present invention also provides pharmaceutical compositions comprising various combinations of modified
  • FVII/FVIIa mutants may comprise a single pharmaceutical composition, wherein such mutants may comprise mutations that are preferably comprising the EGF-1 domain, or at one, more than one, or all amino acid residues at positions 53, 62, 74, 75, 83, or any combination thereof.
  • Such pharmaceuticals are in accordance with the embodiments of the present invention and provide for increased synergistic biological effectiveness.
  • compositions comprising modified FVII/FVIIa, or any products thereof, such as nucleotide or amino acid products, such as mutant proteins or peptides according to the present invention, or sequences comprising the corresponding mutant FVII
  • a pharmaceutical composition of the present invention comprises modified FVII/FVIIa according to the present invention, or complexes of modified FVII/FVIIa and a pharmaceutically accepted carrier.
  • a pharmaceutical composition according to the present invention may comprise a mutant FVII factor, such a FVII (K62E) , FVII (K62T) , or any mutant combination of FVII, such as mutation (s) comprising the EGF-1 domain with mutation (s) at residues one or more or any combination of mutations at residues -53, 62, 74, 75, 83, or any vector encoding the same, or any cell comprising the sequence information and cellular machinery and conditions permitting the expression of said mutant factors .
  • a mutant FVII factor such as FVII (K62E) , FVII (K62T)
  • any mutant combination of FVII such as mutation (s) comprising the EGF-1 domain with mutation (s) at residues one or more or any combination of mutations at residues -53, 62, 74, 75, 83, or any vector encoding the same, or any cell comprising the sequence information and cellular machinery and conditions permitting the expression of said mutant factors .
  • the present invention also provides a method for treating a patient with a bleeding disorder, or any blood related condition, such as patients with thrombocytopenia, comprising introducing into the patient, the FVII mutant peptide or protein, a vector, preferably an expression vector encoding a modified FVII/FVIIa according the a preferred embodiment of the present invention, in a pharmaceutically effective amount .
  • a preferred pharmaceutical composition of the present invention comprises an effective amount of mutant FVII mutant protein, or peptide, wherein said FVII mutant is as embodied in the present invention.
  • a patient is provided with a pharmaceutically effective amount of a pharmaceutical composition according to the present inventio .
  • a method for treating a patient with a pharmaceutical composition according to the present invention wherein said modified FVII/FVIIa may be complexed to another molecule, or may be encapsulated in an acceptable vehicle, such as a lipid vesicle.
  • the present invention additionally provides a strategy for selecting amino acid residues for mutagenesis, wherein said method aims to produce mutants with enhanced biological activity, or modulated enzymatic activity, wherein the method comprises: comparison of enzymatic activity of related interspecies native enzymes or protein for a specific substrate ' or antigen; comparison of the nucleotide or amino acid sequences of said native enzymes or proteins with enhanced or altered activities; determination of the non-conserved nucleotide or amino acid sequence ' s between said native enzymes or proteins; specific modification of said non-conserved nucleotide or amino acid residues to yield mutant enzymes or proteins; determination of change in biological activity of said enzymes with respect to said native enzymes or proteins; and the expression and purification of said mutant enzymes or proteins .
  • a method for making mutants with enhanced or modulated enzymatic activity comprises: a) comparison of enzymatic activity of related interspecies native enzymes or protein for a specific substrate or antigen; b) comparison of the nucleotide or amino acid sequences of said native enzymes or proteins with enhanced or altered activities;- c) determination of the non-conserved nucleotide or amino acid sequences between said native enzymes or proteins; d) specific modification of said non-conserved nucleotide or amino acid residues to yield mutant enzymes or proteins; e) determination of change in biological activity of said enzymes with respect to said native enzymes or proteins; f) expression and purification of, said mutant enzymes or ⁇ proteins.
  • said modification is via site-directed mutagenesis.
  • said modification may be at single points, or any more than one loci.
  • said modification (s) may yield a mutant library, where said library comprises mutant enzymes or proteins with mutations at any one of said non-conserved nucleotide or amino acid residue for the • mutant libraries may be generated.
  • modification may be effected via site-directed mutagenesis, at single amino acid residues, or more than one residue loci.
  • modification (s) may yield a mutant library, where said library comprises mutant enzymes or proteins with mutations at any one of said non-conserved nucleotide or amino acid residue for the mutant libraries may be generated.
  • a FVII/FVIIa mutant library and more preferably a human FVII/FVIIa mutant library comprising various FVII/FVIIa mutants, wherein mutations to FVII/FVIIa are at one or more residue (s) comprising the EGF-1 domain.
  • the mutant library of the present invention may comprise FVII mutants with mutations at one or more residue positions 53, 62, 74, 75, 83, or any combination thereof, wherein said FVII mutant library comprises a plurality of FVII mutants that may be screened to select additional FVII mutants with increased biological activity.
  • FVII/FVIIa shall refer to a product consisting of either the unactivated form (FVII) or the activated form (FVIIa) or mixtures thereof.
  • FVII/FVIIa comprises proteins that have the amino acid sequence of native FVII/FVIIa, and includes proteins with, slightly modified amino acid ' sequences, wherein such slight modifications may be in N-terminal amino acids or amino acid variations in the N-terminal region that do not affect FVIIa activity, and may also include naturally occurring allelic variations that may exist in native human FVII/FVIIa.
  • FVII, FVIIa or FVII/FVIIa may be used interchangeably in the present disclosure
  • Modified FVII/FVIIa shall refer to a biologically active molecule derived from FVII/FVIIa by the substitution of one or more amino acid residues.
  • modified FVII/FVIIa may also be identified as mutant FVII/FVIIa.
  • FVII (AxyB) or AxyB refers to mutant FVII/FVIIa comprising a point mutation from amino acid A (A) to amino, acid B (B) at amino acid residue xy of FVII/FVIIa.
  • FVII (S53N) or S53N would accordingly refer to mutant FVII/FVIIa comprising a point mutation from Serine (S) to Asparagine (N) at amino acid 53 of FVII/FVIIa.
  • Bio activity shall refer to a function or set of functions performed by a molecule in a biological context (i.e. in an organism or an in ' vitro facsimile).
  • biological activity may refer to catalytic and effector activities.
  • Biological activity may refer to binding affinity, which preferably refers to the binding of FVII/FVIIa to TF, or to clotting activity, which is preferably refers to the ability to initiate the coagulation cascade.
  • Fig. 1 illustrates an alignment diagram of the EGF-1 domains of human FVII and rabbit FVII;
  • the N-terminal amino acid residues 46-83 of FVII were aligned using the software program GENEPRO.
  • the 5 non-conserved amino acid residues at positions 53, 62, 74, ' 75 and 83 are highlighted in bold.
  • Fig. 2 Transient expression of human rFVII mutant proteins.
  • Human wild-type (WT) rFVII and the rFVII EGF1 domain mutant proteins S53N, K62E, P74A, A75D, T83K and rabEGFl were transiently expressed in HEK293 cells.
  • FVII antigen concentration was determined by human FVII- specific ELISA. Data are the means ⁇ SEM, n ⁇ 3.
  • Fig.3. Analysis of purified rFVIIa mutant proteins by SDS-PAGE. Electrophoretogram stained with coomassie blue. Lanes 1-6 contained a protein MW standard, plasma-derived FVIIa (ERL), wild-type rFVII (Novo Nordisk Inc., NN) , rFVIIa (K62E) , rFVIIa (A75D) and wild-type rFVIIa (Genentech Inc., Gen) respectively.
  • ERP plasma-derived FVIIa
  • NN wild-type rFVII
  • K62E wild-type rFVIIa
  • A75D wild-type rFVIIa
  • Fig. 4 represents the inhibition of binding of biotinylated plasma-derived FVII to full-length, relipidated, human TF in a competitive ELISA developed in our laboratory.
  • the IC 50 for rFVII (K62E) was calculated to be 5-fold lower than for either plasma-derived or wild-type rFVII.
  • the data illustrate the relative affinity of purified rFVII (K62E) mutant protein for TF via inhibition of binding of biotinylated plasma-derived zymogen FVII to full-length, relipidated human TF via competitive ELISA.
  • the seminal role of the first epidermal growth factor-like (EGF1) domain of human factor VII (FVII) in binding to tissue factor (TF) has been established.
  • the variable activity of TF from various animal species in initiating coagulation in heterologous plasma is well known.
  • Increased coagulant activity of rabbit plasma (i.e. FVII) with human TF might be explained by the 5 non-conserved amino acids in the rabbit versus the human FVII EGF1 domain.
  • Total rFVII mutant protein antigen secreted ranged from 18% to 135% of wild-type rFVII (112 ng/ml medium) . Clotting activity of the unpurified rFVII mutant proteins was either depressed or unchanged. Amidolytic activity of the unpurified rFVII mutant proteins as not significantly different from wild-type rFVII. Notably, 3/6 unpurified rFVII mutant proteins had increased affinity for human TF in the rank order rFVII (rabEGFl) [3.3-fold] > rFVII ( K62E) [2.9-fold] > rFVII (A75D) [1.7-fold] .
  • HEK293 cell line permanently expressing rFVII (K62E) was established and ' the mutant protein was purified to homogeneity from the serum-free culture medium by Q-Sepharose ion-exchange chromatography.
  • Purified rFVII (K62E) had 1.9-fold greater clotting activity and 5-fold greater affinity for TF as compared to human rFVII (WT) .
  • the K D of rFVII (K62E) for soluble human TF was 1.3 nM compared to 7.2 nM for rFVII (WT) .
  • FVII a 50 kDa glycoprotein of human plasma [1] is essential for the initiation of the clotting cascade in man [2,3].
  • FVIIa activated FVII
  • TF-mediated signal transduction [4,5] tumor angiogenesis and metastasis • [6,7]
  • inflammatory response during disseminated intravascular coagulation [8] a number of strategies have been explored in attempts to inhibit the FVII-TF interaction. This is a daunting biological task as both zymogen FVII and FVIIa bind with high affinity to soluble human TF with a K D of 7.5 nM and 5.1 nM respectively [9].
  • New, potentially important anticoagulants include humanized monoclonal antibodies to TF [10] and variants of human soluble TF . [11] .
  • a different approach has resulted in the description of inhibitory peptides to exosites in the - heavy chain of human FVII [12,13].
  • studies of both natural [14-16] and site-directed mutants of FVII [17] have universally described FVII mutant proteins with decreased affinity for TF.
  • the impetus for this work was an early observation of Janson et al [18] who described a 4-fold increased clotting activity of rabbit plasma (i.e FVII) versus human plasma (FVII) on incubation with human TF.
  • the present invention is directed to mutants of FVII EGF-1 domain. More specifically, the present invention is directed towards mutants of human FVII EGF-1 which increase biological activity of FVII/FVIIa, and more preferably the affinity of FVII/FVIIa for TF, and the resulting enhanced coagulation activity.
  • a mutant of human recombinant factor VII (K62x) , wherein x is preferably E, i.e mutant FVII (K62E) , or any other mutant with . improved biological activity, such as mutant K62T, i.e mutant FVII (K62T) .
  • a cell line permanently expressing rFVII (K62E), or any of the other rFII mutants exhibiting improved affinity has been established in accordance with the present invention.
  • the recombinant protein namely rFVIIa (K62E) , has been purified to homogeneity in milligram quantities.
  • results with purified rFVIIa indicate that it has at least a 5-fold greater affinity for human TF than does wild-type rFVIIa, as determined by competitive ELISA (please refer to Fig. 4) .
  • a subsequent blinded experiment confirmed the 5-fold increased affinity of rFVIIa (K62E) for TF, where the confirmatory blinded experiment was performed independently by surface plasmon resonance technology.
  • Quantitation of the coagulant activity of rFVII (K62E) by prothrombin time (PT) assay have indicated that it has 1.5 to 2-fold enhanced enzymatic activity in vitro (as identified in Table 2 below) .
  • mutants of FVII such as the mutants provided in the present invention
  • mutants of human rFVIIa with either increased enzymatic activity (in hemophilia) or increased affinity for TF (a better competitive inhibitor) for thrombosis associated with disseminated intravascular coagulation (DIC) , atherosclerosis and cancer.
  • mutants of human rFVIIa with increased affinity for TF and/or clotting activity could make the current use of wild-type rFVIIa obsolete.
  • enzymatically-inactive mutant forms' of rFVIIa with high- affinity for TF could become novel anticoagulants .
  • FVII-TF interaction i.e. FVII from rabbits and mice both exhibited dramatically increased enzymatic activity with human TF rather than with homologous TF, and the allosteric interaction (s) between the FVII EGF-1 and protease domains modulated both TF binding and the enzymatic activity of FVII were noted to be of significance.
  • This evidence sequentially precipitated the exchanging of 5 amino acids of the human FVII EGF-1 domain for those of rabbit FVII [20] using site-directed mutagenesis technology [15] .
  • point amino acid mutations made were S53N, K62E, K62D, K62N, K62Q, K62T, P74A, A75D, T83K i.e. the human FVII EGF-1 domain was "rabbitized" at each of these non-conserved amino acid residues resulting in the creation of unique variants of human FVII.
  • Each of the recombinant human FVII chimeric c ' DNAs were then transfected into human kidney 293 (HEK) cells and transient expression, of the FVII chimeric proteins at levels of 20-120 ng FVII antigen/ml culture media was observed.
  • Preliminary characterization of the above unpurified, FVII mutant proteins indicated that several of the mutant proteins, and in particular FVII(K62E) had increased affinity for TF.
  • Cloning vector pUC19 DNA was from New England Biolabs (Beverly, MA) . Plasmid DNA was amplified in Escherichia coli XL-1 Blue (Stratagene, La Jolla, CA) . Oligonucleotide synthesis and automated DNA sequence analysis were performed in the molecular biology facility MOBIX, McMaster University. Dulbecco's Modified Eagles (DMEM)-Ham's F12 media was from Sigma-Aldrich Co. (St. Louis, MO) . The tissue culture medium supplement bovine albumin-insulin-transferrin (BIT 9500) was from Stem Cell Technologies (Vancouver, BC) .
  • DMEM Dulbecco's Modified Eagles
  • BIT 9500 bovine albumin-insulin-transferrin
  • Oligonucleotide site- directed mutagenesis (Clontech, Palo Alto, CA) was performed on the FVII EGFl domain in the vector pUC19 as previously described [15-] .
  • the mutagenic primers employed were:
  • K62 ⁇ N (5 ' -GGGCTCCTGCAACGACCAGCTC-3 ' )
  • K62 ⁇ Q (5'-GGGCTCCTGCCAGGACCAGCTC-3' )
  • rFVII rabbit EGFl domain
  • rFVII rabbit EGFl domain
  • Rabbit FVII EGFl domain DNA was ' prepared using rabbit FVII template cDNA [20] by a standard polymerase ' chain reaction utilizing the forward primer:
  • HEK293 cells were routinely maintained in DMEM-F12 medium supplemented with 10% fetal calf serum, lOOU/ml penicillin-streptomycin and 100 ng/ml vitamin K.
  • HEK293 cell conditioned media were collected for analysis 72 hr post-transfection and concentrated 6-fold by • Amicon ultrafiltration prior to quantitation by FVII-specific ELISA.
  • HEK293 cell lines permanently expressing recombinant FVII (rFVII) mutants FVII (A75D) and FVII (K62E) established essentially as described [20] .
  • both FVII mutant cDNAs were subcloned into the EcoRI-Hindlll site of the expression vector pCMV5 and co-transfected into HEK293 cells with the selection plasmid pSV2neo. After 2-3 weeks post-transfection, G418-resistant clones were assayed for synthesis of human FVII by ELISA.
  • Optimal FVII- synthesizing cell clones were expanded into NUNC triple- flask cell factories and the supernatant medium was collected weekly.
  • rFVII from HEK293 cell conditioned medium was greatly facilitated by the use of serum-free, phenol red-free DMEM-F12 supplemented with 1 mg/ml bovine serum albumin, 1 ⁇ g/ml bovine insulin, 20 ⁇ g/ml human transferring (BIT) , 100 ng/ l vitamin K and penicillin-streptomycin.
  • Confluent HEK293 cells remained adherent to the plastic substratum and continued to synthesize rFVII normally for 3-4 weeks in the above medium.
  • FVII mutant proteins were purified from serum-free HEK293 conditioned medium using a modification of the Q-
  • Sepharose pseudoaffinity chromatography technique [23] . Briefly, HEK293 cell serum-free conditioned medium was collected and filtered through one layer of Whatman No. 1 filter paper. Benza idine and Na 2 EDTA were added to final concentrations of 10 mM and 5 mM respectively. The medium was stored frozen at -40°C. One liter of HEK293 cell conditioned medium was concentrated to 250 ml using a Millipore pump and PLTK prep-scale TFF cartridge (30,000 kDa molecular weight cut-off).
  • the 250 ml concentrate was dialyzed overnight against 20 mM Tris, pH 8.0, 50 mM NaCl, 0.05% azide, 1 mM benzamidine, 1 mM EDTA at 4°C.
  • the dialyzed sample was readjusted to 10 mM benzamidine and 5 mM EDTA. Conductivity of the dialyzed sample was routinely less than 10 ⁇ mhos . If not, distilled water was added.
  • Q-Sep ' harose fast flow (1.5 x 25 cm, bed volume 50 ml) was equilibrated with 3 column volumes of 20 mM Tris pH 8.0, 50 mM NaCl, 10 mM benzamidine, 5 mM EDTA.
  • the purity of the starting rFVII concentrate and the eluted protein were analyzed by SDS-PAGE and Western blot analysis using biotinylated, monospecific sheep anti-FVII IgG. A second passage over Q-Sepharose was needed to achieve 95%+ pure material. For the second stage, a column of 4-5 ml bed volume, applying maximum 20-25 mg total protein per ml gel was used. Once again protein was bound using the low ionic strength equilibration buffer but eluted with 5 mM CaCl 2 . In some purifications final removal of albumin from FVII K62E, or other FVII mutant, was accomplished using sheep anti-BSA IgG coupled to sepharose.
  • Total rFVII/rFVIIa antigen levels were determined by solid- phase enzyme-linked immunoabsorbent assay (ELISA) as previously described [20] . Briefly, the assay incorporated monospecific polyclonal sheep anti-human FVII IgG as the trapping antibody and biotinylated monospecific polyclonal sheep anti-human FVII IgG as the detecting antibody. Biotinylated antibody binding was quantitated using streptavidin-alkaline phosphatase and the enzyme substrate PNPP. Either purified plasma-derived human FVII or purified human rFVII were used to generate a standard curve.
  • ELISA solid- phase enzyme-linked immunoabsorbent assay
  • Coagulant and Amidolytic Activity of rFVII Mutant Proteins Coagulant activity of the various FVII samples was measured by prothrombin time(PT) assay using FVII- depleted human plasma and relipidated full-length human thromboplastin as previously described [24] .
  • Amidolytic activity of rFVIIa was the chromogenic peptide substrate S-2222 was determined as described [24] . Determination of the Relative Affinity of rFVII Mutant Proteins for TF by Competitive ELISA.
  • the human FVII molecule was "rabbitized” at each of these amino acid residues to create rFVII (S53N) , rFVII (K62E) , rFVII (P74A), rFVII (A75D) and rFVII (T83K) .
  • additional mutations such as mutations K62D, K62N, K62Q, K62T are also provided in the present invention.
  • rFVII liposome- itiediated pCMV5
  • rFVII mutant proteins and rFVII were expressed at levels between 70-130 ng rFVII/ml culture medium, with the exception of rFVII (A75D) and rFVII (rabEGFl) which were expressed / secreted at significantly at lower levels.
  • the biological activity of the transiently-expressed, unpurified rFVII mutant proteins were then compared to rFVII (WT) .
  • Specific activities of the rFVII mutant proteins for either the peptidyl substrate S-2222 (amidolytic assay) or a macromolecular substrate (PT assay) were not statistically different from wild-type rFVII (data not shown) .
  • mutants S53N
  • K62E mutants
  • the present invention contemplates all mutations at ' one or more, or any combination of mutations at positions 53, 62, 74, 75 and 83 of the EGF-1 domain of FVII, wherein the mutations embodied in the present invention exhibit improved biological activity.
  • mutation K62E, or K62T, or A75D, or any other single or multiple point mutation embodied in the present invention showing improved biological activity is embodied herein.
  • Such improved biological activity may comprise an increase in binding affinity for TF, improved anti-coagulant or anti-inflammatory activities.
  • K62 rFVII EGFl mutants ⁇ increased biological activities where K62 rFVII EGFl mutants .
  • all rFVII EGFl domain mutants exhibiting improved biological activities, such as increased clotting activity are embodied in the preset invention.
  • mutants -K62D, K62E, K62N, K62Q, and K62T have been shown to exhibit increased clotting " activity, where mutant K62T showed the most improved increase in clotting activity, where clotting activity was increased 2.3-fold compared to the wild- type.
  • Table 2 summarizes the relative FVII coagulant activity for some rFVII EGFl K62 mutants, wherein all mutants summarized exhibit increased clotting activity with respect to the wild-type FVII.
  • the asterisk* represents statistical difference (p ⁇ 0. 05) as compared to wild-type ' factor VII [FVII (WT) ] .
  • rFVII Purified rFVII (K62E) .
  • K62E Functional Analysis of Purified rFVII (K62E) .
  • rFVII (K62E) was permanently expressed in HEK293 cells and purified to homogeneity from 1-2 liters of HEK293 serum-free conditioned medium. After purification via pseudoaffinity chromatography on Q-Sepharose ion-exchange resin rFVII (K62E) was >95% pure as judged by SDS-PAGE with coomassie blue staining and western blot analysis (data not shown) . Purification of rFVII (K62E) resulted in 10- 20% activation of rFVII (K62E) to rFVIIa (K62E) .
  • wt-rFVII purified commercial wild-typ (wt) rFVIIa from Novo Nordisk Inc.
  • wt-FVII 2 plasma-derived human FVII from Enzyme Research Labs * affinity increase of binding between rFVII mutant and human TF, as determined by competitive ELISA (as described in [24])
  • wt-FVII 2 plasma-derived human FVII from Enzyme Research Labs clotting activity 3 (as described in [24] ) clotting activity 3 (as described in [24]) amidolytic activity 4 (as described in [24]) binding affinity 5 of recombinant FVII mutants to full-length, relipidated human TF, relative to wt-rFVII, as determined by competitive ELISA (as described in [24])
  • Table 5 summarizes the changes in FVII mutant affinities for human TF.
  • the data show the normalized competitive ELISA IC 50 values (ng FVII/ml) for inhibition of biotinylated plasma FVII binding to relipidated, full-length human TF. Data are the means ⁇ SEM, n ⁇ 3. The asterisk * represents p ⁇ 0.05 as compared to the mean of FVII (WT) .
  • the first epidermal growth factor-like domain of human coagulation FVII is essential for high-affinity binding to its cell surface receptor TF [14, 19, 26, 27].
  • replacement of the entire human FVII EGFl domain with the homologous rabbit FVII EGFl region resulted in the formation of a chimeric human rFVII (rabEGFl) molecule which was poorly secreted from HEK293 cells (Fig. 2) but, in the unpurified form, exhibited greater than a 3-fold increase in affinity for TF (Table 5) and an approximate 2-fold increase in specific clotting activity with human TF relative to pdFVII (data not shown) .
  • Recombinant FVIIa is currently approved for use in Canada in hemophilia A patients with acquired inhibitors to factor VIII.
  • the chemical amounts of rFVIIa required is a minimum of 2-3 bolus injections of 90 ug rFVII/kg body weight [39] due to the competition of patient plasma FVII zymogen with the infused rFVIIa for available TF [40] .
  • rFVIIa currently constitutes the second most costly drug purchased by the Canadian Blood Services, Canada's blood agency.
  • rFVIIai chemically inactivated rFVIIa
  • rFVIIai chemically inactivated rFVIIa
  • mutants of the present invention wherein the preferred mutants of the present .invention exhibit increased affinity for TF, and/or improved biological activity, may be used to enhance hemostasis in both hemophilia patients with circulating inhibitors and patients with thrombocytopenia, and may additionally be used as anti-coagulant-,and/or anti-inflammatory compounds for the treatment and/or prophylaxis of patients with thrombosis, disseminated intravascular coagulation or cancer.
  • compositions effective for modulating the biological activity of FVII/FVIIa in a mammal, and preferably a human are encompassed in the present invention.
  • a pharmaceutical composition of the present invention may comprise at least one modified factor FVII/FVIIa (mutant FVII/FVIIa) as herein described, or complexes or fragments thereof.
  • a pharmaceutical composition of the present invention comprises a modified' form of factor FVII/FVIIa (mutant FVII/FVIIa) having a mutation at residue 62 thereof, such as mutation K62E, .
  • a composition of the present invention improves FVII/FVIIa binding of TF and improves blood coagulation.
  • a pharmaceutical composition of the present invention comprises a purified or unpurified protein, peptide, polypeptide, or functional fragment thereof for mutant FVII/FVIIa (K62E) , or any mutant embodied herein having improved biological activity, or a nucleotide sequence or fragment thereof, in a vehicle (vector, cell,, compound, vesicle) capable of providing and/or expressing mutant FVII/FVIIa in, or to ' , said patient.
  • a vehicle vector, cell,, compound, vesicle
  • the invention provides modulators (e.g., effectors) of FVII/FVIIa activity and their therapeutic administration. These compounds include one or more of the FVII/FVIIa mutants prepared and/or identified by the methods of the invention.
  • a compound that can be used therapeutically also includes a purified polypeptide, immunogenic polypeptide or polypeptide fragment, nucleotide sequence, vector or cell of the present invention.
  • the peptides, polypeptides and other compounds and/or compositions of the invention are administered with a pharmaceutically acceptable carrier (s) (excipient) to form the pharmaceutical composition.
  • compositions of the present invention can be delivered alone or as pharmaceutical compositions by any means known in the art, e.g., . systemically, regionally, or locally; by intraarterial, intrathecal (IT), intravenous (IV), parenteral, intra- pleural cavity, topical, oral, or local administration, as subcutaneous, intra-tracheal (e.g., by aerosol) or transmucosal (e.g., buccal, bladder, vaginal, uterine, rectal, nasal mucosa) .
  • IT intraarterial, intrathecal
  • IV intravenous
  • parenteral intra- pleural cavity
  • topical oral
  • oral or local administration
  • subcutaneous, intra-tracheal e.g., by aerosol
  • transmucosal e.g., buccal, bladder, vaginal, uterine, rectal, nasal mucosa
  • the pharmaceutical compositions can be administered by any protocol and in a variety of unit dosage forms depending upon the method of administration, and the like.
  • Dosages for typical peptide and polypeptide pharmaceutical compositions are well known to those of skill in the art. Such dosages are typically advisorial in nature and are adjusted depending on a variety of factors, such as the particular therapeutic context, patient health and the like.
  • the dosage schedule and amounts effective for this use, i.e., the "dosing regimen” will depend upon a variety of factors, including the stage of the disease being treated; timing of co-administration of other agents; the general state of the patient's health; the patient's physical status; age; the pharmaceutical formulation, and the like.
  • the dosage regimen also takes into consideration pharmacokinetics, e.g., the peptide pharmaceutical composition's rate of absorption, bioavailability, metabolism,. clearance, and the like, see, e.g., Remington .
  • Dosages can be determined empirically, e.g, by abatement or amelioration of symptoms, or by objective criteria, analysis of blood or histopathology specimens, and the like.
  • Vectors used for therapeutic administration of modified factor FVII/FVIIa mutant-encoding nucleic acids may be viral or nonviral .
  • Viral vectors are usually introduced into a patient as components of a virus.
  • Illustrative viral vectors into which one can incorporate nucleic acids include, for example, adenovirus-based vectors (Cantwell (1996) Blood 88:4676-4683; Ohashi (1997) Proc. Nat ' 1. Acad. Sci USA 94:1287-1292), Epstein- Barr virus-based vectors (Mazda (1997) J. Immunol. Methods 204:143-151), adenovirus-associated virus vectors, Sindbis virus vectors (Strong (1997) Gene Ther. 4: 624-627), herpes simplex virus vectors (Kennedy (1997) Brain 120: 1245-1259) and retroviral vectors (Schubert (1997) Curr. Eye Res. 16:656-662).
  • Nonviral vectors encoding products useful in gene therapy can be introduced into an animal by means such as lipofection, biolistics, virosomes, liposomes, immunoliposomes, polycation: nucleic acid conjugates, naked DNA injection, artificial virions, agent-enhanced uptake of DNA, ex vivo transduction.
  • lipofection is described in e.g., U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., Transfectam.TM. and Lipofectin.TM. ) .
  • Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Feigner, WO 91/17424 and WO 91/16024. Naked DNA genetic vaccines are described in, for example, U.S. Pat. No. 5,589,486.
  • a method of treating a mammal having a blood condition is provided, such as hemophilia, or thrombocytopenia, or thrombosis associated with disseminated intravascular coagulation (DIC) , or atherosclerosis and cancer.
  • a blood condition includes a compromised ability to adequate maintain blood coagulation.
  • a method of treatment as herein provided includes administration of one or more modified form(s) of factor Vll/VIIa in vivo.
  • a modified form of factor Vll/VIIa is in the form of a pharmaceutical composition.
  • a modified form of factor Vll/VIIa is delivered to a mammal in vivo with an expression vector. That is, a modified form of factor Vll/VIIa is expressed in vivo by an expression vector appropriately delivered to a recipient in need of the modified form of factor Vll/VIIa.
  • Dickinson CD Kelly CR
  • Ruf W Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor Vila. Proc Natl Acad Sci USA 1996; 93: 14379-14384.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The application relates to modified blood coagulation factor, sequencing encoding such modified factors, processes for their production, and related pharmaceutical compositions comprising such factors and their uses. More specifically, the application relates to mutations in the human FVII EGF-1 domain, wherein said mutations were analyzed for clotting activity, amidolytic activity and affinity of binding to full-length, relipidated human TF by competitive ELISA.

Description

MUTANTS OF THE FACTOR VII EPIDERMAL GROWTH
FACTOR DOMAIN
CROSS-REFERENCE TO RELATED APPLICATIONS This application relates to previously filed U.S. Provisional Application S.N. 60/476,905 filed June 5, 2003.
TECHNICAL FIELD
The invention relates to mutants of Factor VII in the epidermal growth factor-like domain. The invention is further related to pharmaceutical compositions comprising such mutant factors and their uses .
BACKGROUND OF THE INVENTION
Human factor VII (FVII) is a 406 amino acid [1] single-chain 50 kDa glycoprotein essential for the initiation of the blood coagulation cascade, as described in United States Patent No. 5,580,560. FVII is synthesized in the liver and is secreted into the blood where it circulates predominately, approximately 98%, as an inactive zymogen precursor of activated factor VII
(FVIIa) , the serine protease that plays a key role in the initiation of the blood coagulation cascade. The binding of FVII to its specific cell-surface receptor tissue factor (TF) , a calcium-dependent reaction of FVII with the transmembrane TF, converts the single-chain zymogen
FVII to the two-chain enzymatically-active FVIIa form.
The activation of FVII to FVIIa involves the hydrolysis of a single peptide bond between Argl52 and Ilel53, thereby resulting in a two-chain molecule consisting of a light chain of 152 amino acids residues, and a heavy chain of 254 amino acid residues held together by a single disulfide bond.
FVII and FVIIa are multidomain proteins comprising an N-terminal Gla domain (γ-carboxyglutamic acid domain) , which confers the ability of FVII' or FVIIa to. bind, in a reversible calcium-dependent manner to membranes containing negatively charged phospholipids, followed by two epidermal growth factor (EGF) -like domains, referred to as the EGF-1 and EGF-2, and a serine protease domain. These domains appear to be involved, to different extends, in an optimal interaction with TF.
Initiation of coagulation begins with the binding of either FVII or FVIIa to TF on the cell membrane. It is now well established that the first epidermal growth factor-like domain (EGF-1) of FVII is essential for the high affinity binding to TF [26, 15] . Analysis of the
FVIIa-sTF, a complex of active site-inhibited human FVIIa with a protease-cleaved form of human soluble tissue factor (sTF) , crystal structure [19] has shown that 70% of the binding energy between the two molecules involved amino acid residues in the EGF1 domain of FVII, yet this domain comprises only 38 of the 406 amino acids of human FVII. It should also be noted that the FVII-TF interaction
(i.e. human FVII - human TF interaction) is one of high affinity, the Kd being variously estimated between 10~9 to
10~10 M.
The variable activity of TF from various animal tissues in the initiation of coagulation has been known [18] . Accordingly, it has been shown that the FVII-TF interaction is species-specific. For example, FVII from rabbits and FVII from mice both exhibited dramatically increased enzymatic activity with human TF when compared with homologous TF [18] .
The FVII EGF-1 domain of FVII provides the region of greatest contact during the interaction of FVIIa with TF. Leonard et al have shown that allosteric interactio (s) between the FVIIa active site (contained within the protease domain) and the EGF-1 domain is sensitive to variation in active site occupant structure, thereby indicating that the conformational change associated with FVII activation and active site occupation involves the EGF-1 domain [33] . Since the interaction of FVII with TF appears to play a critical role in coagulation, and other important biological processes, an understanding of the mechanisms by which the EGF-1 domain of FVII interacts with TF is of particular relevance and importance . Moreover, since the establishment of allosteric interaction (s) between the FVII EGF-1 and protease domains modulated both TF binding and the enzymatic activity of FVII, an examination of the FVII EGF-1 domain with a view to developing mutants of FVII with enhanced activity and/or affinity, for TF would be of significant importance.
SUMMARY OF THE INVENTION
The present invention fulfills a great need in the present art. The annual usage of recombinant FVIIa in
Canada alone is estimated to be $20, 000, 000/annum.
Mutants of human rFVIIa with increased affinity for TF and/or clotting activity could make the current use of wild-type rFVIIa obsolete. Furthermore, enzymatically- inactive forms of high-affinity rFVIIa mutants for TF could become novel anticoagulants.
An aim of the present invention is to provide FVII/FVIIa mutants with enhanced biological activity, enzymatic activity and/or binding affinity for TF. A preferred aim of the ' present invention is to provide human FVII/FVIIa mutants with enhanced biological activity, and more preferably, enhance'd enzymatic activity and/or affinity for TF.
Accordingly, the present invention provides modified FVII/FVIIa mutants with enhanced biological activity, enzymatic activity and/or binding affinity for TF via site-directed mutagenesis of selected amino acids.
It has been determined that the increased clotting activity of rabbit FVII with human TF, compared to human FVII with human TF, may be explained by 5 non-conserved amino acid residues in the rabbit FVII EGF-1 versus the human FVII EGF-1 domain. More specifically, the 5 non- conserved amino acid residues are located at positions 53, 62, 74, 75, 83 of the EGF-1 domain, as illustrated in Fig. 1.
The present invention provides a modified factor Vll/VIIa (also referred to herein as mutant FVII/FVIIa (or rFVII, rFVII, or rFVII/rFVIIa) , preferably human FVII/FVIIa, comprising one or more mutation(s), wherein the mutation (s) is/are in the epidermal growth factorlike (EGF-1) domain. More specifically, the present invention provides modified FVII/FVIIa comprising one or more mutation(s), wherein the mutation (s) is/are in the epidermal growth factor-like (EGF-1) domain, and in a preferred embodiment of the invention, the mutation (s) is/are at one, more than one, or all amino acid residues at residues 53, 62, 74, 75, 83, or any combination thereof, wherein the mutation may be to any amino acid residue that confers enhanced biological activity of FVII/FVIIa to, for example, positively improve blood coagulation, or increase affinity for TF. Accordingly, a mutation embodied by the present invention may be mutant FVII (K62x) , wherein amino acid x is selected from any amino acid residue that increases the biological activity of FVII, such as the binding affinity of FVII for TF, or the clotting activity of FVII, or the amidolytic activity of FVII, or any functional activity that facilitates or improves the initiation of the blood coagulation cascade.
More particularly, the modified FVII/FVIIa mutants of the present invention comprise one, more than one or all mutations selected from (S53N) , (K62E) , (P74A) ,
(A75D) , or (T83K) , or any combination thereof. In addition, the present invention also provides mutations
K62D, K62N, K62Q, and K62T, wherein the presence of mutation K62T confers improved biological activity to the mutant rFVII (K62T) when compared to wild-type FVII. For example, a mutation embodied by the present invention may be mutant FVII (S53N) (K62E) , FV I(K62T), FVII (S53N) (K62T) , or FVII(K62E) (T83K) , or any combination of mutations FVII(S53N), FVII (K62E) , FVII (K62D) , FVII (K62N) ,
FVII(K62Q), and FVII (K62T) , FVII (P74A) , FVII (A75D) , FVII(T83K) or any other mutation or combination of mutations at residues 53, 62, 74, 75, or 83 of in the EGF-1 of FVII. In a preferred embodiment of the invention, the modified FVII/FVIIa is FVII(K62E), where FVII(K62E) is a modified human FVII/FVIIa comprising a K to E mutation at amino acid residue 62. In another preferred embodiment of the invention, the modified FVII/FVIIa is FVII (K62T) , where FVII (K62T) is a modified human FVII/FVIIa comprising a K to T mutation at amino acid residue 62. Table 2 below provides some FVII mutants with enhanced coagulant activity.
The present invention also provides a modified polypeptide, immunogenic polypeptide, or polypeptide fragment comprising a modified FVII/FVIIa' according to the present invention, wherein said modified FVII/FVIIa more specifically comprises mutations of the EGF-1 domain, and preferably mutations at one, more than one, or all amino acid residues at positions 53, 62, 74, 75, 83, or any combination thereof.
A modified FVII/FVIIa according to the present invention provides enhanced biological activity, and more specifically enhanced enzymatic activity and/or affinity for TF.
The present invention also provides nucleotide sequence of an isolated nucleotide sequence comprising a sequence that encodes a purified polypeptide, immunogenic polypeptide, or polypeptide fragment of a modified FVII/FVIIa according to the present invention, wherein said modified FVII/FVIIa' more specifically comprises mutation (s) within the EGF-1 domain, or mutations at one, more than one, or all amino acid residues at positions 53, 62, 74, 75, 83, or any combination thereof.
The invention also comprises recombinant nucleotide, or isolated nucleotide sequences encoding modified FVII/FVIIa according to the present, wherein said modified FVII/FVIIa more specifically comprises mutation (s) within the EGF-1 domain, or mutations at one, more than one, or all amino acid residues at positions 53, 62, 74, 75, 83, or any combination thereof, or any degenerate variant thereof.
The degeneracy of the genetic code is well known, wherein, most amino acid residues t are encoded by more than one codon sequence, i.e. different codons can encode the same amino acid. Although certain nucleotide sequences noted herein encode specific codons to specific mutant amino acids in the various FVII mutants of the present invention, it is understood that other degenerate variant nucleotide sequences comprising differing codons for the equivalent mutant amino acids are also encompassed by the nucleotide sequences of the present invention. For example, mutant FVII(P74A) may be encodes by different but equivalent nucleotide sequences wherein mutant amino. acid A, Alanine, may be encoded by different, codons, such as GCA or GCC. Accordingly, primers directed towards the production of Ala may, comprise different Ala codons, and will yield equivalent amino acid products. Accordingly, the nucleotide sequences of the present invention also comprise degenerate variants thereof. In a preferred embodiment, the present invention comprises nucleotide sequence comprising a nucleotide sequence, for example, a cDNA or degenerate variant thereof, that encodes a modified FVII/FVIIa of the present invention, wherein said nucleotide sequence specifically hybridizes to a sequence selected from SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, or any degenerate variant thereof. SEQ ID NO:l to SEQ ID NO 4 are mutagenic primers of a preferred embodiment of the invention, wherein the highlighted codon encodes the mutagenic amino acid, and where said primer sequences bind to complementary nucleotide sequences, such as cDNAs, encoding modified FVII/FVIIa according to the present invention. Accordingly, the present invention also comprises mutagenic primers noted below, and any degenerate variants thereof, and additionally comprises nucleotide sequence and degenerate variants to the modified FVII/FVIIa that hybridized said mutagenic primer.
S53→N (5'-GTGTGCCTCAAACCCATGCCAGAATG-3') (SEQ ID NO:21)
K62→E (5'-GGGCTCCTGCGAGGACCAGCTC-3' ) (SEQ ID NO: 22)
K62→D (5'-GGGCTCCTGCGACGACCAGCTC-3') (SEQ ID NO: 23)
K62→N (5'-GGGCTCCTGCAACGACCAGCTC-3') (SEQ ID NO: 24)
K62→Q (5'-GGGCTCCTGCCAGGACCAGCTC-3') (SEQ ID NO: 25) K62→T (5'-GGGCTCCTGCACGGACCAGCTC-3') (SEQ ID NO:26)
P74→A (5'-GCTTCTGCCTCGCTGCCTTCGAG-3') (SEQ ID NO:27)
A75→D (5'-CTGCCTCCCTGACTTCGAGGGC-3' ) (SEQ ID NO:28)
T83→K (5'-GCCGGAAGTGTGAGAAACACAAGGATGACC-3') (SEQ IDNO:29)
K62→X (5'-GGGCTCCTGCNNNGACCAGCTC-3') (SEQ ID NO: 30) , wherein NNN of SEQ ID NO: 30 is a codon that encodes any amino acid the improves the' biological activity of FVII, through the modification of residue 62 of the EGF-1 domain of FVII.
For example, in an embodiment of the invention, the mutations effected, at each codon are:
SERINE53(5'AGT-3' ) TO SPARAGINE (5ΑAC-31 LYSINE62 (5ΑAG-3') TO GLUTAMIC ACID (5'GAG-3'
LYSINE62 (5ΑAG-3') TO ASPARTIC ACID (5'GAC-3'-
LYSINE62 (5ΑAG-3') TO ASPARAGINE (5*AAC-3'
LYSINE62 (5ΑAG-3') TO GLUTAMINE (5'CAG-3'
LYSINE62 (5ΑAG-3') TO THREONINE (5ΑCG-31 LYSINE62 (5'AAG-3') TO THREONINE (5ΑCG-3'
LYSINE62 (5'AAG-3') TO ANY AMINO ACID "(5'NNN-3'
PROLINE74 (5*CCT-3') TO ALANINE (5'GCT-3'
ALANINE75 (5'GCC-3') TO ASPARTIC ACID (5'GAC-3'
THREONINE83 (5ΑCG-3') TO LYSINE (5'AAA-3'
As noted above, the present invention provides for any mutant FVII (K62x) , or any FVII mutant comprising a mutation at K62, wherein amino acid x is selected from any amino acid residue that increases the biological activity of FVII, such as the binding affinity of FVII for TF, or the clotting activity of FVII, or the amidolytic activity of FVII, or any functional activity that facilitates or improves the initiation of the blood coagulation cascade. Although not all FVII K62 mutations are noted herein, the present invention embodies all K62 mutations, or any FVII mutants comprising a mutation at K62 l of the EGF-1 domain, having improved of increased biological activity when compared to wild type FVII.
Accordingly, preferred embodiments of the present invention also comprise recombinant nucleotide sequences encoding modified FVII/FVIIa mutants according to the present invention, or any degenerate variant thereof, wherein said modified FVII/FVIIa more specifically comprises mutation (s) within the EGF-1 domain, or mutations at one, more than one, or all amino acid residues at positions 53, 62, 74, 75, 83, or any combination thereof.
Accordingly, the present invention also comprises corresponding nucleotide sequences encoding modified FVII/FVIIa mutants of the present invention and any degenerate variants thereof. The Sequence listings provided for the nucleotide and amino acid sequences of the FVII/FVIIa mutants comprises the sequence of the EGF- 1 domain, however it is understood that the present invention embodies the functional full length FVII/FVIIa mutant, or- any functional fragment thereof, where the modified EGF-1 domain of said modified FVII/FVIIa mutant is provided herein. Accordingly, the present invention provides: SEQ ID NO:l, SEQ ID NO 2, SEQ ID NO: 3 , SEQ ID NO:4 , SEQ ID NO:5, SEQ ID NO: 6, SEQ ID N0:7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, wherein SEQ ID NO: 1-10 refer to nucleotide sequences, wherein degenerate equivalents are also embodied, herein, of the EGF-1 domain of the mutant FVII (xABy) . Accordingly the present invention embodies any FVII mutant sequence comprising the nucleotide sequence of the EGF-1 domain comprising a sequence of any one of SEQ ID NO: 1-10 or any degenerate equivalent thereof. The present invention also comprises any vector comprising the FVII mutant sequences embodied herein, wherein said vector may be an expression vector, preferably pCMV5, or a cloning vector, preferably pUCl9. Also ' provided is a culture cell, cell or cell line, preferably HEK293, CHO or BHK cells or any related cell or progeny thereof, wherein said culture cell, cell or cell line is transfected with a FVII modified nucleotide sequences, wherein said- modified nucleotide sequences comprises a modified EGF-1 domain sequence of any one of SEQ ID NO: 1-10.
The present invention also provides SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO: 11, which correspond to the amino acid sequence of the modified EGF-1 domain comprises in the modified FVII/FVIIa (xABy) protein, or functional fragment thereof embodied herein, as provided by the nucleotide sequence of SEQ ID NO: 1-10. Accordingly the present invention embodies any FVII mutant sequence comprising the amino acid sequence of the EGF-1 domain comprising a sequence of any one of SEQ ID NO: 11-20 or any functional variant or equivalent thereof. It should be further noted that the present invention embodies the functional full length FVII/FVIIa mutant, or any functional fragment or equivalent thereof, where the modified EGF-1 domain of said modified FVII/FVIIa mutant is provided herein, as specified in SEQ ID NO: 11-20. The modified modified FVII/FVIIa (xABy) of the present invention may be produced as full length or as biologically active functional fragments thereof, wherein the mutant protein or polypeptide embodied herein exhibits improved biological activity compared to the FVII/FVIIa wild type. The modified FVII mutants embodied herein may be expressed, isolated- and purified according to known protein and polypeptide procedures .
Also provided are the mutagenic primers having SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, and SEQ ID NO:30, wherein SEQ ID NO:21-28 comprise mutagenic primers that hybridizes to the nucleotide sequences of SEQ ID NO: 1-10, respectively.
In a preferred embodiment, the present application provides modified FVII/FVIIa, or functional fragment thereof, comprising one or more mutation(s), wherein said mutation (s) are in the EGF-1 domain, and are preferably any any one, more than one, or all residues 53, 62, 74, 75, or 83 of the EGF-1 of FVII/FVIIa, provided that said mutation as residues 53, 62, 74, 75, or 83 results in a modified FVII/FVIIa having improved biological activity with respect to the wild type FVII. More preferably, the modified FVII mutant comprises a mutation at K62 of the EGF-1 domain, wherein the mutation at K62 confers enhanced biological activity-.
In an embodiment of the present invention there is provided ' a modified FVII/FVIIa protein, or biologically active fragment thereof, wherein the modified FVII/FVIIa comprises mutation (s) at any one of residues 53, 62, 74, 75, or 83 of the EGF-1, or any combination thereof. In a preferred embodiment, the present invention provides a modified FVII/FVIIa (K62x) protein, or biologically active fragment thereof, and more preferably a modified ■ FVII/FVIIa (K62E) protein or functional equivalent thereof.
It is additionally noted that the present invention also comprises any degenerate variants of the nucleotide sequences according to the present invention. Moreover, the present invention also comprises cDNA nucleotide sequences and degenerate variants, that encode modified FVII/FVIIa, wherein said modified FVII/FVIIa more specifically comprises mutation (s) within the EGF-1 domain, or mutations at one, more than one, or all amino acid residues at positions 53, 62, 74, 75, 83, or any combination thereof.
According to a preferred embodiment, the present invention comprises a nucleotide sequence comprising any one of SEQ ID NO: 1-10, or any nucleotide sequence that comprises a sequence (s) encoding one, more than one, or all mutations at residues 53, 62, 74, 75, 83 of the EGFl domain of FVII/FVIIa, or any combination thereof, or any degenerate variant thereof, that yields a modified FVII/FVIIa according to the present invention. Therefore, the present invention additionally comprises a nucleotide sequence, such as a cDNA, that encodes for a modified FVII/FVIIa mutant comprising mutation (s) at one, more than one, or all ■ amino acid residues at positions 53, 62, 74, 75, 83, of human FVII/FVIIa, or any combination thereof.
The present invention comprises nucleotide sequence that encodes a polypeptide with the amino acid sequence of Fig.l, or a polypeptide comprising any single or individual mutation contained therein, or any multiple mutations, or any combinations thereof.
The present invention also provides a vector comprising a nucleotide sequence encoding a modified FVII/FVIIa according to the present invention, and more specifically, a wherein said modified FVII/FVIIa more specifically comprises mutation (s) within the EGF-1 domain, or mutations at one, more than one, or all amino acid residues at positions 53, 62, 74, 75, 83, or any combination thereof.
The present invention also provides vectors comprising all the 'various nucleotide sequences of the present invention, wherein said nucleotide sequences encode a modified FVII/FVIIa according to the present invention, or equivalents thereof, such as protein fragments, or (poly) peptides, or other equivalent functional molecules. In a preferred embodiment, a vector of the present invention may be an expression vector, preferably pCMV5, or, a cloning vector, preferably pUCl9.
In accordance with the present invention there is provided a culture cell or cell line transfected with a vector Recording to the present invention, or a progeny of said cell, wherein said culture cell or cell line, preferably HEK293, CHO, or BHK cells, or any other cell of human or non human origin suitable for the expression of a modified FVII/FVIIa of the present invention, or for the pharmaceutical, clinical or therapeutic uses thereof, wherein said cell or cell line is capable of expressing modified FVII/FVIIa according to the present invention or functional equivalents thereof.
The present invention also provides a culture cell or cell line that permanently expresses a mutant or modified nucleotide sequence of a modified FVII/FVIIa according to the present invention, wherein said culture cell or cell line is transfected with a vector according to the present invention and, may be preferably co- transfected with a selection plasmid, such as pSV2neo.
In a preferred embodiment, the present invention provides a culture cell or cell line that expresses a modified FVII/FVIIa according to the present invention, wherein the cell is preferably HEK293, CHO, or BHK cells, or any other cell of human or non human origin suitable for the expression of a modified FVII/FVIIa of the present invention, or for the pharmaceutical, clinical or therapeutic uses thereof, wherein said cell or cell line is capable of expressing modified FVII/FVIIa according to the present invention or functional equivalents thereof. In a preferred embodiment of the present invention, an HEK293, CHO or BHK culture cell or cell line that expresses a modified FVII (K62E) or FVII(A75D), or any other modified FVII/FVIIa according to the present invention, that is, any FVII/FVIIa (AxyB) molecule, and preferably any human FVII/FVIIa (AxyB) molecule, wherein A is a wild type amino acid, xy is the location of said amino acid, preferably comprised in the EGF-1 domain, and more preferably in the EGF-1 domain of human FVII/FVIIa, and more specifically at one, more than one, or all amino acid residues at positions 53, 62, 74, 75, 83, or any combination thereof, where B is said mutant amino acid.
The present invention also provides a cell, or cell line comprising the recombinant nucleotide molecule encoding a mutant FVII according to the present invention. According to a preferred embodiment, the present invention provides a cultured cell, or cell line comprising a vector according to the present invention, wherein said culture cell or cell line is preferably HEK293, CHO or BHK CELLS.
Moreover, the present invention also comprises HEK293 cell lines which permanently express recombinant FVII/FVIIa mutants. In a preferred embodiment, the mutant nucleotide sequences, or cDNAs, of mutants FVII(K62E), and/or FVII (A75D) , or other modified FVII/FVIIa of the present invention, were subcloned into an expression vector, preferably pCMV5 expression vector and co-transfected into a cell, preferably HEK293 cell line along with a selection plasmid, preferably pSV2neo. Although permanent cell lines expressing mutants K62E and A75D have been established, the present invention also comprises the establishment of other permanent cell lines including CHO and BHK cells to other FVII/FVIIa mutants according to the present invention.
According to a preferred embodiment of the present invention, there is provided human FVII mutants "* wherein mutations considered are, in the EGF-1 domain, and more specifically at positions 53, 62, 74, 75, 83, or any combination thereof, wherein residues S53, K62, P74, A75, T83 may be mutated to any amino acid residue that increases the biological activity of FVII/FVIIa and preferably modified human FVII/FVIIa, to positively improve blood coagulation.
In a preferred embodiment of the present invention, there is provided a modified or mutant protein factor, or equivalent thereof, wherein said protein factor is human FVII/FVIIa, and where at least one amino acid in the EGF- 1 domain. In a preferred embodiment, a modified or mutant protein factor, or equivalent thereof comprises mutation (s) preferably at residue positions 53, 62, 74, 75, 83, has - been substituted with another amino acid which confers increased functional activity, such as binding affinity to TF, or clotting affinity, to said mutant factor. In a preferred embodiment, one, more or all the amino acid residues at S53, K62, P74, A75, T83 have been mutated to FVII(S53N), FVII(K62E), FVII (K62D) , FVII(K62N), FVII (K62Q) , FVII (K62T) , FVII (P74A) , FVII(A75D), FVII(T83K), or any combination thereof.
Accordingly, it should be further noted that the present invention is contemplated to cover any combination of mutations at any amino acid residue comprised in the EGF-1 domain, , and more preferably at residues S53, K62, P74, A75, T83 of human FVII/FVIIa.
The invention is further directed to a method of expressing a modified factor Vll/VIIa according to the present invention or equivalent thereof, in a cell, preferably cell line HEK293, wherein the method comprises: providing an expression vector, preferably pCMV5, encoding the modified protein; introducing the vector into the cell; and maintaining the cell under conditions permitting the expression of the protein in the cell . The method of the present invention also provides for the expression of the modified FVII/FVIIa in vivo or in vitro in other permanent cell lines.
In a preferred embodiment of the present invention, the present invention provides mutant human FVII(K62E), wherein the mutant factor exhibits significantly increased clotting activity when compared to plasma- derived human FVII/FVIIa. Combinations of other FVII mutants according to the invention, such as FVII (K62E) , , and FVII (A75D) aim to further increase the 'biological .activity of the FVII, and preferably of human FVII.
The present invention also- comprises a cell transformed with a recombinant nucleotide molecule comprising an isolated nucleotide sequence, and degenerate variants thereof, encoding a mutant or modified FVII protein or equivalent thereof, wherein said i mutations are at one or more than one residue of the EGF-
1 domain, and more preferably at one, more than one, or all residues 53, 62, 74, 75, or 83 or combinations thereof. Mutant FVIIa can be obtained by activating mutant FVII.
There is also provided an expression vector and a cloning vector encoding modified human FVII cDNA, wherein said expression vector is preferably pCMV5 or another suitable expression vector, said cloning vector is preferably pUC19 or another suitable expression vector, and wherein said cDNA is nucleotide sequence encoding a modified FVII/FVIIa, and preferably a modified human FVII/FVIIa, wherein the mutation to FVII may be any mutation according to the present invention. More specifically, said mutation- may be at any amino acid comprising the EGF-1 domain of FVII, and preferably at any one of, more than one, or all amino acid residues 53, 62, 74, 75 and 83 or any combination thereof.
The present invention also provides a pharmaceutical composition comprising a modified FVII/FVIIa mutant product, or equivalent thereof, such as a functional peptide fragment, or other fragment, according to the present invention, or complexes of said modified FVII/FVIIa and a pharmaceutically accepted carrier.
The present invention further provides a method of treating a patient with condition or disorder, such as a bleeding disorder, or treating patients with thrombocytopenia, wherein the method comprises introducing into the patient a pharmaceutically effective amount of a modified FVII/FVIIa, and preferably a modified human FVII/FVIIa according to the invention, or any functional equivalent thereof, or an expression vector encoding a modified human FVII protein, such that an amount of the modified protein is effective to improve blood coagulation. In another embodiment of the method of the present invention, there is provided a modified human FVII with increased binding affinity for TF, or a modified human FVII-TF complex, wherein the . amounts of the modified FVII protein, or the complexed modified FVII are in amounts effective to improve blood coagulation.
The present invention provides a method of treating a patient, preferably a patient with a bleeding condition or other blood related condition, such as patients with thrombocytopenia or other conditions, where said method comprises administration of a pharmaceutically effective amount of a modified FVII/FVIIa according to the invention, wherein said modified FVII/FVIIa more specifically comprises mutation (s) within the EGF-1 domain, or mutations at one, more than one, or all amino acid residues at positions 53, 62, 74, 75, 83, or any combination thereof.
The present invention also provides pharmaceutical compositions comprising various combinations of modified
FVII/FVIIa according the a preferred embodiment of the present invention, wherein one or more various differing
FVII/FVIIa mutants may comprise a single pharmaceutical composition, wherein such mutants may comprise mutations that are preferably comprising the EGF-1 domain, or at one, more than one, or all amino acid residues at positions 53, 62, 74, 75, 83, or any combination thereof.
Such pharmaceuticals are in accordance with the embodiments of the present invention and provide for increased synergistic biological effectiveness.
There is also provided a pharmaceutical composition comprising modified FVII/FVIIa, or any products thereof, such as nucleotide or amino acid products, such as mutant proteins or peptides according to the present invention, or sequences comprising the corresponding mutant FVII
- sequence or equivalents thereof, 'according to the present invention, or complexes of said modified FVII/FVIIa and a pharmaceutically accepted carrier and pharmaceutically acceptable vehicles, such as lipid encapsulation vesicles. A pharmaceutical composition of the present invention comprises modified FVII/FVIIa according to the present invention, or complexes of modified FVII/FVIIa and a pharmaceutically accepted carrier. Preferably, a pharmaceutical composition according to the present invention may comprise a mutant FVII factor, such a FVII (K62E) , FVII (K62T) , or any mutant combination of FVII, such as mutation (s) comprising the EGF-1 domain with mutation (s) at residues one or more or any combination of mutations at residues -53, 62, 74, 75, 83, or any vector encoding the same, or any cell comprising the sequence information and cellular machinery and conditions permitting the expression of said mutant factors .
The present invention also provides a method for treating a patient with a bleeding disorder, or any blood related condition, such as patients with thrombocytopenia, comprising introducing into the patient, the FVII mutant peptide or protein, a vector, preferably an expression vector encoding a modified FVII/FVIIa according the a preferred embodiment of the present invention, in a pharmaceutically effective amount .
In a preferred embodiment, a preferred pharmaceutical composition of the present invention comprises an effective amount of mutant FVII mutant protein, or peptide, wherein said FVII mutant is as embodied in the present invention. In accordance with a preferred treatment of the present invention, a patient is provided with a pharmaceutically effective amount of a pharmaceutical composition according to the present inventio .
A method . for treating a patient with a pharmaceutical composition according to the present invention, wherein said modified FVII/FVIIa may be complexed to another molecule, or may be encapsulated in an acceptable vehicle, such as a lipid vesicle.
In another embodiment, the present invention additionally provides a strategy for selecting amino acid residues for mutagenesis, wherein said method aims to produce mutants with enhanced biological activity, or modulated enzymatic activity, wherein the method comprises: comparison of enzymatic activity of related interspecies native enzymes or protein for a specific substrate ' or antigen; comparison of the nucleotide or amino acid sequences of said native enzymes or proteins with enhanced or altered activities; determination of the non-conserved nucleotide or amino acid sequence's between said native enzymes or proteins; specific modification of said non-conserved nucleotide or amino acid residues to yield mutant enzymes or proteins; determination of change in biological activity of said enzymes with respect to said native enzymes or proteins; and the expression and purification of said mutant enzymes or proteins .
Accordingly, there is provided a method for making mutants with enhanced or modulated enzymatic activity, wherein said method comprises: a) comparison of enzymatic activity of related interspecies native enzymes or protein for a specific substrate or antigen; b) comparison of the nucleotide or amino acid sequences of said native enzymes or proteins with enhanced or altered activities;- c) determination of the non-conserved nucleotide or amino acid sequences between said native enzymes or proteins; d) specific modification of said non-conserved nucleotide or amino acid residues to yield mutant enzymes or proteins; e) determination of change in biological activity of said enzymes with respect to said native enzymes or proteins; f) expression and purification of, said mutant enzymes or < proteins. In a preferred embodiment, said modification is via site-directed mutagenesis. In another preferred embodiment, said modification may be at single points, or any more than one loci. Furthermore, said modification (s) may yield a mutant library, where said library comprises mutant enzymes or proteins with mutations at any one of said non-conserved nucleotide or amino acid residue for the • mutant libraries may be generated.
In a preferred embodiment of the above noted mutation strategy method, modification may be effected via site-directed mutagenesis, at single amino acid residues, or more than one residue loci.
In another embodiment of the above noted mutant strategy method of the present invention, there is provided a method wherein modification (s) may yield a mutant library, where said library comprises mutant enzymes or proteins with mutations at any one of said non-conserved nucleotide or amino acid residue for the mutant libraries may be generated.
In a preferred embodiment of the present invention, there is provided a FVII/FVIIa mutant library, and more preferably a human FVII/FVIIa mutant library comprising various FVII/FVIIa mutants, wherein mutations to FVII/FVIIa are at one or more residue (s) comprising the EGF-1 domain. In a more preferred embodiment, the mutant library of the present invention may comprise FVII mutants with mutations at one or more residue positions 53, 62, 74, 75, 83, or any combination thereof, wherein said FVII mutant library comprises a plurality of FVII mutants that may be screened to select additional FVII mutants with increased biological activity.
For the purpose of the present invention, the following terms are defined below.
FVII/FVIIa shall refer to a product consisting of either the unactivated form (FVII) or the activated form (FVIIa) or mixtures thereof. FVII/FVIIa comprises proteins that have the amino acid sequence of native FVII/FVIIa, and includes proteins with, slightly modified amino acid' sequences, wherein such slight modifications may be in N-terminal amino acids or amino acid variations in the N-terminal region that do not affect FVIIa activity, and may also include naturally occurring allelic variations that may exist in native human FVII/FVIIa. Although distinctions have been made, FVII, FVIIa or FVII/FVIIa may be used interchangeably in the present disclosure
Modified FVII/FVIIa shall refer to a biologically active molecule derived from FVII/FVIIa by the substitution of one or more amino acid residues. For the purpose of the this disclosure, modified FVII/FVIIa may also be identified as mutant FVII/FVIIa. FVII (AxyB) or AxyB refers to mutant FVII/FVIIa comprising a point mutation from amino acid A (A) to amino, acid B (B) at amino acid residue xy of FVII/FVIIa. For example, FVII (S53N) or S53N would accordingly refer to mutant FVII/FVIIa comprising a point mutation from Serine (S) to Asparagine (N) at amino acid 53 of FVII/FVIIa.
For convenient reference, the amino acid abbreviations commonly used in the art are summarized below:
Amino Acid 3 letter abbreviation 1 letter abbreviation
__
Alanine Ala
Cysteine Cys C A Assppaarrttaattee A Asspp D
Glutamate Glu E
Phenylalanine Phe F
Glycine Gly G
Histidine His H I Issoolleeuucciinnee l Hiee I
Lysine Lys K eucine Leu L
Methionine Met M
Asparagine Asn N P Prroolliinnee P Prroo p
Glutamine Gin Q
Arginine Arg R
Serine Ser S
Threonine Thr T V Vaalliinnee V Vaall V
Tryptophan Trp W .
Tyrosine Tyr Y γ-carbσxyglutamic acid Gla V
Biological activity shall refer to a function or set of functions performed by a molecule in a biological context (i.e. in an organism or an in ' vitro facsimile). For the purpose of this disclosure, biological activity may refer to catalytic and effector activities. Biological activity may refer to binding affinity, which preferably refers to the binding of FVII/FVIIa to TF, or to clotting activity, which is preferably refers to the ability to initiate the coagulation cascade.
BRIEF DESCRIPTION OF THE DRAWINGS Further features and advantages of the present invention will become apparent from the following detailed description, taken in combination with the appended drawings, in which:
Fig. 1 illustrates an alignment diagram of the EGF-1 domains of human FVII and rabbit FVII; The N-terminal amino acid residues 46-83 of FVII were aligned using the software program GENEPRO. The 5 non-conserved amino acid residues at positions 53, 62, 74, '75 and 83 are highlighted in bold.
Fig. 2 Transient expression of human rFVII mutant proteins. Human wild-type (WT) rFVII and the rFVII EGF1 domain mutant proteins S53N, K62E, P74A, A75D, T83K and rabEGFl were transiently expressed in HEK293 cells. FVII antigen concentration was determined by human FVII- specific ELISA. Data are the means ± SEM, n ≥ 3.
Fig.3. Analysis of purified rFVIIa mutant proteins by SDS-PAGE. Electrophoretogram stained with coomassie blue. Lanes 1-6 contained a protein MW standard, plasma-derived FVIIa (ERL), wild-type rFVII (Novo Nordisk Inc., NN) , rFVIIa (K62E) , rFVIIa (A75D) and wild-type rFVIIa (Genentech Inc., Gen) respectively.
Fig. 4 represents the inhibition of binding of biotinylated plasma-derived FVII to full-length, relipidated, human TF in a competitive ELISA developed in our laboratory. The IC50 for rFVII (K62E) was calculated to be 5-fold lower than for either plasma-derived or wild-type rFVII. Standard FVII = plasma-derived zymogen FVII (Enzyme Research Labs) ; Gentech FVII = wild-type zymogen rFVII (Genentech Inc.); K62E rFVII zymogen was purified in the laboratory of the inventors / applicants.
The data illustrate the relative affinity of purified rFVII (K62E) mutant protein for TF via inhibition of binding of biotinylated plasma-derived zymogen FVII to full-length, relipidated human TF via competitive ELISA.
It will be noted that throughout the appended drawings, like features are identified by like reference numerals .
DETAILED DESCRIPTION OF THE INVENTION
The seminal role of the first epidermal growth factor-like (EGF1) domain of human factor VII (FVII) in binding to tissue factor (TF) has been established. The variable activity of TF from various animal species in initiating coagulation in heterologous plasma is well known. Increased coagulant activity of rabbit plasma (i.e. FVII) with human TF might be explained by the 5 non-conserved amino acids in the rabbit versus the human FVII EGF1 domain. Accordingly, using recombinant DNA methodology, we have "rabbitized" the human FVII EGF1 domain either by exchanging the entire EGF1 domain creating human FVII (rabEGFl) or by the single amino acid substitutions S53N, K62E, P74A, A75D, T83K, and other K62 mutations, such as K62D, K62N, K62Q, K62T. After transient expression in HEK293 cells, supernatant medium containing the unpurified, recombinant FVII (rFVII) mutant proteins were analyzed for coagulant activity, amidolytic activity and affinity of binding to full- length, relipidated human TF by competitive ELISA. Total rFVII mutant protein antigen secreted ranged from 18% to 135% of wild-type rFVII (112 ng/ml medium) . Clotting activity of the unpurified rFVII mutant proteins was either depressed or unchanged. Amidolytic activity of the unpurified rFVII mutant proteins as not significantly different from wild-type rFVII. Notably, 3/6 unpurified rFVII mutant proteins had increased affinity for human TF in the rank order rFVII (rabEGFl) [3.3-fold] > rFVII ( K62E) [2.9-fold] > rFVII (A75D) [1.7-fold] . To further validate these results a HEK293 cell line permanently expressing rFVII (K62E) was established and ' the mutant protein was purified to homogeneity from the serum-free culture medium by Q-Sepharose ion-exchange chromatography. Purified rFVII (K62E) had 1.9-fold greater clotting activity and 5-fold greater affinity for TF as compared to human rFVII (WT) . The KD of rFVII (K62E) for soluble human TF was 1.3 nM compared to 7.2 nM for rFVII (WT) . We conclude that interspecies substitution of selected amino acid residues of the human FVII EGF1 domain confirms the primary role of the EGF1 domain in TF binding. This strategy facilitates the creation of mutants of human FVII with both enhanced biological activity and/or affinity for TF.
FVII, a 50 kDa glycoprotein of human plasma [1] is essential for the initiation of the clotting cascade in man [2,3]. Recent evidence has supported a role for activated FVII (FVIIa) in TF-mediated signal transduction [4,5], tumor angiogenesis and metastasis • [6,7] and the inflammatory response during disseminated intravascular coagulation [8] . In the quest for new anticoagulant and anti-inflammatory drugs, a number of strategies have been explored in attempts to inhibit the FVII-TF interaction. This is a formidable biological task as both zymogen FVII and FVIIa bind with high affinity to soluble human TF with a KD of 7.5 nM and 5.1 nM respectively [9]. New, potentially important anticoagulants include humanized monoclonal antibodies to TF [10] and variants of human soluble TF . [11] . A different approach has resulted in the description of inhibitory peptides to exosites in the - heavy chain of human FVII [12,13]. To date studies of both natural [14-16] and site-directed mutants of FVII [17] have universally described FVII mutant proteins with decreased affinity for TF. The impetus for this work was an early observation of Janson et al [18] who described a 4-fold increased clotting activity of rabbit plasma (i.e FVII) versus human plasma (FVII) on incubation with human TF. Since 43 % of the contact area of TF with FVII lies within the FVII EGFl domain [19] we believe, and have shown, that the difference in FVII clotting activities noted above might reside in the 5 amino acid residues which differ between the rabbit [20] and human FVII EGFl domains. Accordingly, we have both substituted the entire rabbit EGFl domain and the corresponding rabbit amino acid for its human counterpart at each of these 5 residues. This has resulted in the creation of human FVII mutant proteins with enhanced affinity for human TF and increased enzymatic activity. The present invention is directed to mutants of FVII EGF-1 domain. More specifically, the present invention is directed towards mutants of human FVII EGF-1 which increase biological activity of FVII/FVIIa, and more preferably the affinity of FVII/FVIIa for TF, and the resulting enhanced coagulation activity.
In accordance with preferred embodiment of the present invention, there is provided a mutant of human recombinant factor VII (K62x) , wherein x is preferably E, i.e mutant FVII (K62E) , or any other mutant with . improved biological activity, such as mutant K62T, i.e mutant FVII (K62T) . In addition, a cell line permanently expressing rFVII (K62E), or any of the other rFII mutants exhibiting improved affinity, has been established in accordance with the present invention. The recombinant protein, namely rFVIIa (K62E) , has been purified to homogeneity in milligram quantities. Results with purified rFVIIa (K62E) indicate that it has at least a 5-fold greater affinity for human TF than does wild-type rFVIIa, as determined by competitive ELISA (please refer to Fig. 4) . A subsequent blinded experiment, confirmed the 5-fold increased affinity of rFVIIa (K62E) for TF, where the confirmatory blinded experiment was performed independently by surface plasmon resonance technology. Quantitation of the coagulant activity of rFVII (K62E) by prothrombin time (PT) assay have indicated that it has 1.5 to 2-fold enhanced enzymatic activity in vitro (as identified in Table 2 below) .
The developments of the present invention are especially useful, and comprise scientific and clinical significance. More specifically, recombinant human FVIIa (NovoSeven from Novo Nordisk), i.e. a purified commercial wild-type fFVIIa, is currently being used clinically in hemophilia A patients with antibody to factor VIII [39] but the amounts required are high due to the competition of patient zymogen plasma FVII with rFVIIa for available TF [45] . Artificially inactivated human rFVIIa, called rFVIIai, has been shown to effectively inhibit thrombosis and death in a baboon model of DIC [8] . Both of these potential uses of human rFVIIa would be greatly facilitated by the advent of mutants of FVII, such as the mutants provided in the present invention, with either increased enzymatic activity (in hemophilia) or increased affinity for TF (a better competitive inhibitor) for thrombosis associated with disseminated intravascular coagulation (DIC) , atherosclerosis and cancer. Moreover, as noted above, mutants of human rFVIIa with increased affinity for TF and/or clotting activity could make the current use of wild-type rFVIIa obsolete. Furthermore, enzymatically-inactive mutant forms' of rFVIIa with high- affinity for TF could become novel anticoagulants .
The species-specific FVII-TF interaction, i.e. FVII from rabbits and mice both exhibited dramatically increased enzymatic activity with human TF rather than with homologous TF, and the allosteric interaction (s) between the FVII EGF-1 and protease domains modulated both TF binding and the enzymatic activity of FVII were noted to be of significance. This evidence sequentially precipitated the exchanging of 5 amino acids of the human FVII EGF-1 domain for those of rabbit FVII [20] using site-directed mutagenesis technology [15] . In accordance with an embodiment of the present invention, point amino acid mutations made were S53N, K62E, K62D, K62N, K62Q, K62T, P74A, A75D, T83K i.e. the human FVII EGF-1 domain was "rabbitized" at each of these non-conserved amino acid residues resulting in the creation of unique variants of human FVII. Each of the recombinant human FVII chimeric c'DNAs were then transfected into human kidney 293 (HEK) cells and transient expression, of the FVII chimeric proteins at levels of 20-120 ng FVII antigen/ml culture media was observed. Preliminary characterization of the above unpurified, FVII mutant proteins indicated that several of the mutant proteins, and in particular FVII(K62E) had increased affinity for TF.
Table 1. Coagulant Activity of Purified Recombinant FVII (K62E)
Figure imgf000033_0001
Legend: Purified commercial wild-type (wt) rFVII was from Genentech Inc. Plasma-derived human FVII was from Enzyme Research Labs Inc. (ERL) . rFVII (A75D) and rFVII (K62E) were purified from serum-free HEK293 cell culture medium by Q-Sepharose ion-exchange chromatography. A conventional prothrombin time (PT) clotting assay was performed using FVII-depleted pooled human plasma and recombinant human, relipidated TF. The asterisks** indicate a highly significant difference between the clotting activities of rFVII (K62E) and rFVII- Genentech (p ≤ 0. 01 , n=3) . Statistical analysis was by ANOVA using the InStat3 software package.
Subsequently, both humanized monoclonal antibodies to human TF and several variants of human TF have been described [10] . Research with human FVII has resulted in the description of inhibitory peptides to several exosites in human FVII [46] as well as mutants of the FVII heavy chain with increased intrinsic enzymatic activity [38] .
To date, studies of both natural [16] and synthetic mutants of FVII [17] have universally described FVII molecules with decreased enzymatic activity and affinity for TF. In contrast, the earlier .work of Janson et al
[18] described 4-fold increased clotting activity of rabbit plasma FVII versus human plasma FVII with human TF. Since 43% of the contact area of TF with FVII lies within the FVII EGF-1 domain [19] we postulated that the difference in FVII clotting activities noted above might reside in the 5 amino acid residues which differ in the rabbit [20] and human FVII EGF-1 domains.
Accordingly, ' individual, and combinatorial, substitution within the human FVII EGF-1 domain, and more specifically, at one, more or all these 5 amino acid positions for the corresponding rabbit amino acid has resulted in the creation of 'rabbitized' human FVII mutant proteins with enhanced affinity for human TF and increased enzymatic activity.
PRODUCTION OF FVII/FVIIa MUTANTS EXPERIMENTAL PROCEDURES
Reagents Human FVII cDNA was subcloned in the EcoRI- HindiII site of the expression vector pCMV5 as described [15] . Cloning vector pUC19 DNA was from New England Biolabs (Beverly, MA) . Plasmid DNA was amplified in Escherichia coli XL-1 Blue (Stratagene, La Jolla, CA) . Oligonucleotide synthesis and automated DNA sequence analysis were performed in the molecular biology facility MOBIX, McMaster University. Dulbecco's Modified Eagles (DMEM)-Ham's F12 media was from Sigma-Aldrich Co. (St. Louis, MO) . The tissue culture medium supplement bovine albumin-insulin-transferrin (BIT 9500) was from Stem Cell Technologies (Vancouver, BC) .
Site-Directed Mutagenesis . Oligonucleotide site- directed mutagenesis (Clontech, Palo Alto, CA) was performed on the FVII EGFl domain in the vector pUC19 as previously described [15-] . The mutagenic primers employed were:
S53→N (5 ' -GTGTGCCTCAAACCCATGCCAGAATG-3 ' ) ,
K62→E (5 ' -GGGCTCCTGCGAGGACCAGCTC-3 ' ) , P74→A (5'-GCTTCTGCCTCGCTGCCTTCGAG-3? ) ,
A75→D (5 ' -CTGCCTCCCTGACTTCGAGGGC-3 ' ) ,
T83→K (5 ' -GCCGGAAGTGTGAGAAACACAAGGATGACC-3 ' ) ,
K62→D (5 ' -GGGCTCCTGCGACGACCAGCTC-3 ' ) ,
K62→N (5 ' -GGGCTCCTGCAACGACCAGCTC-3 ' ) , K62→Q (5'-GGGCTCCTGCCAGGACCAGCTC-3' ) , and
K62→T (5 ' -GGGCTCCTGCACGGACCAGCTC-3 ' ) .
'Human rFVII with a rabbit EGFl domain i.e. rFVII (rabEGFl) was created by site-directed mutagenesis using the unique restriction sites BstEII and Nsil at the 5' and 3' ends of the human FVII EGFl domain respectively. The' BstEII site was generated using the primer:
5 ' -CTTACAGTGATGGTGACCAGTGTGCCTC-3 ' . This base substitution did not change the amino acid sequence of human FVII. The Nsil site was generated using the primer:
5 ' -CGGAACTGTGAGATGCATAAGGATGACCAGC-3 ' .
Creation of the new Nsil restriction site also altered the amino acid sequence of human FVII changing residue T83→M. After excision of the human FVII EGFl domain DNA by BstEII-NsiI restriction endonuclease digestion and subcloning of the rabbit FVII EGFl domain DNA in. its place, the codon . at position 83 was corrected from M83→K by site-directed mutagenesis using the primer:
5 ' -GGTCGCAACTGTGAGAAACACAAGGATGACCAGC-3 ' .
Rabbit FVII EGFl domain DNA was ' prepared using rabbit FVII template cDNA [20] by a standard polymerase ' chain reaction utilizing the forward primer:
5 ' -TACAATGATGGTGACCAGTGTGCCTCC-3 ' ,
and the reverse primer:
5 ' -TCTTATGCATCTCACAGTTGCGACCCTCG-3 ' .
The fidelity of all FVII mutant DNAs were confirmed by automated DNA sequence analysis.
Mammalian Cell Culture and Transient Expression of rFVII Mutant Proteins . Wild-type and mutant FVII cDNAs in the vector pCMV5 were transfected into HEK293 cells using Lipofectin reagent (InVitrogen Corp., San Diego, CA) as previously described [22] . HEK293 cells were routinely maintained in DMEM-F12 medium supplemented with 10% fetal calf serum, lOOU/ml penicillin-streptomycin and 100 ng/ml vitamin K. HEK293 cell conditioned media were collected for analysis 72 hr post-transfection and concentrated 6-fold by • Amicon ultrafiltration prior to quantitation by FVII-specific ELISA.
Permanent Expression of rFVII Mutant Proteins Two
HEK293 cell lines permanently expressing recombinant FVII (rFVII) mutants FVII (A75D) and FVII (K62E) established essentially as described [20] . Briefly, both FVII mutant cDNAs were subcloned into the EcoRI-Hindlll site of the expression vector pCMV5 and co-transfected into HEK293 cells with the selection plasmid pSV2neo. After 2-3 weeks post-transfection, G418-resistant clones were assayed for synthesis of human FVII by ELISA. Optimal FVII- synthesizing cell clones were expanded into NUNC triple- flask cell factories and the supernatant medium was collected weekly. Purification of rFVII from HEK293 cell conditioned medium was greatly facilitated by the use of serum-free, phenol red-free DMEM-F12 supplemented with 1 mg/ml bovine serum albumin, 1 μg/ml bovine insulin, 20 μg/ml human transferring (BIT) , 100 ng/ l vitamin K and penicillin-streptomycin. Confluent HEK293 cells remained adherent to the plastic substratum and continued to synthesize rFVII normally for 3-4 weeks in the above medium.
Purification of rFVII Mutant Proteins . Recombinant
FVII mutant proteins were purified from serum-free HEK293 conditioned medium using a modification of the Q-
Sepharose pseudoaffinity chromatography technique [23] . Briefly, HEK293 cell serum-free conditioned medium was collected and filtered through one layer of Whatman No. 1 filter paper. Benza idine and Na2EDTA were added to final concentrations of 10 mM and 5 mM respectively. The medium was stored frozen at -40°C. One liter of HEK293 cell conditioned medium was concentrated to 250 ml using a Millipore pump and PLTK prep-scale TFF cartridge (30,000 kDa molecular weight cut-off). The 250 ml concentrate was dialyzed overnight against 20 mM Tris, pH 8.0, 50 mM NaCl, 0.05% azide, 1 mM benzamidine, 1 mM EDTA at 4°C. The dialyzed sample was readjusted to 10 mM benzamidine and 5 mM EDTA. Conductivity of the dialyzed sample was routinely less than 10 μmhos . If not, distilled water was added. Q-Sep'harose fast flow (1.5 x 25 cm, bed volume 50 ml) was equilibrated with 3 column volumes of 20 mM Tris pH 8.0, 50 mM NaCl, 10 mM benzamidine, 5 mM EDTA. All subsequent chromatographic steps were at 4°C. The dialyzed, concentrated medium was applied to the column at a flow rate of 2 ml per min. The column was then washed with 5 column volumes of equilibration buffer followed by 5 column volumes of equilibration buffer without EDTA. rFVII was eluted from the column with 250 ml of equilibration buffer without EDTA containing 10 mM CaCl2. The majority of rFVII eluted in the first 150 ml. Eluted rFVII was concentrated to 5 ml by Amicon ultrafiltration. The purity of the starting rFVII concentrate and the eluted protein were analyzed by SDS-PAGE and Western blot analysis using biotinylated, monospecific sheep anti-FVII IgG. A second passage over Q-Sepharose was needed to achieve 95%+ pure material. For the second stage, a column of 4-5 ml bed volume, applying maximum 20-25 mg total protein per ml gel was used. Once again protein was bound using the low ionic strength equilibration buffer but eluted with 5 mM CaCl2 . In some purifications final removal of albumin from FVII K62E, or other FVII mutant, was accomplished using sheep anti-BSA IgG coupled to sepharose.
Quantitation of FVII, FVIIa and Total Protein. Total rFVII/rFVIIa antigen levels were determined by solid- phase enzyme-linked immunoabsorbent assay (ELISA) as previously described [20] . Briefly, the assay incorporated monospecific polyclonal sheep anti-human FVII IgG as the trapping antibody and biotinylated monospecific polyclonal sheep anti-human FVII IgG as the detecting antibody. Biotinylated antibody binding was quantitated using streptavidin-alkaline phosphatase and the enzyme substrate PNPP. Either purified plasma-derived human FVII or purified human rFVII were used to generate a standard curve. Data were plotted as the absorbance ;at 405nm versus the FVII antigen concentration. The assay was linear in the range 1-25 ng/ml FVII antigen. Total protein concentrations were determined either by BCA assay (Pierce Scientific Co., Rockford IL) or the Bradford coomassie blue reagent (Sigma-Aldrich, St. Louis, MO) .
Coagulant and Amidolytic Activity of rFVII Mutant Proteins . Coagulant activity of the various FVII samples was measured by prothrombin time(PT) assay using FVII- depleted human plasma and relipidated full-length human thromboplastin as previously described [24] . Amidolytic activity of rFVIIa was the chromogenic peptide substrate S-2222 was determined as described [24] . Determination of the Relative Affinity of rFVII Mutant Proteins for TF by Competitive ELISA. The binding of biotinylated, plasma-derived FVII to relipidated, full-length rTF and the quantitation of the relative affinity of rFVII mutant proteins for rTF by inhibition of biotinylated FVII binding (IC50) has been described in detail elsewhere [24] .
Determination of the Absolute Affinity of rFVII Mutant Protein for sTF by Surface Plasmon Resonance. An anti-TF antibody was immobilized on the BIAcore flow cell at high density and subsequently reacted with recombinant sTF.- Dilutions of wild-type or mutant FVII molecules were then injected into the BIAcore flow cell and binding kinetics were determined. Data from reference cells containing the same amount of anti-TF antibody but no sTF were subtracted to correct for non-specific binding. The reference cell contained the same amount of anti-TF antibody but no TF [25] .
Statistical Analysis . Linear regression analysis, Student's t test, analysis of variance and standard error of the mean were performed using the InStat 3.05 software package for Windows 98 (GraphPad Software, San
Diego, CA) .
RESULTS
DNA mutagenesis, transient expression and characterization of unpurified human rFVII EGF-1 mutant proteins . Alignment of the 38 amino acids of the human and rabbit FVII EGF-1 domains (Fig.l) illustrates that there are 5 non-conserved amino acids at residues 53{S→N}, 62{K→E}, 74{P→A}, 75{A→D} and 83{T→K}. Using site-directed DNA mutagenesis, the human FVII molecule was "rabbitized" at each of these amino acid residues to create rFVII (S53N) , rFVII (K62E) , rFVII (P74A), rFVII (A75D) and rFVII (T83K) . In addition, it should also be noted, that in addition to mutations that 'rabbitized' the FVII EGF-1, additional mutations, such as mutations K62D, K62N, K62Q, K62T are also provided in the present invention. Nevertheless, the collective effect of all five amino acid changes was examined by restriction endonuclease excision of the human FVII EGFl domain DNA and substitution of the PCR-generated rabbit FVII EGFl DNA to create rFVII (rabEGFl) . Fidelity of the full- length mutant rFVII cDNA sequences was confirmed by automated DNA sequence analysis. The mutant rFVII cDNAs were then excised from pUC19 via EcoRI-Hindlll endonuclease digestion and subcloned into the mammalian expression vector pCMV5. Three days after liposome- itiediated pCMV5 (rFVII) DNA transfection into HEK293 cells, transient expression of wild-type and mutant rFVII molecules was quantitated by FVII-specific ELISA using polyclonal anti-human FVII IgG. Fig.2 represents the' mean rFVII antigen expression observed for each of the 6 mutant human rFVII proteins as compared to wild-type (WT) human rFVII. Generally, rFVII mutant proteins and rFVII (WT) were expressed at levels between 70-130 ng rFVII/ml culture medium, with the exception of rFVII (A75D) and rFVII (rabEGFl) which were expressed / secreted at significantly at lower levels. The biological activity of the transiently-expressed, unpurified rFVII mutant proteins were then compared to rFVII (WT) . Specific activities of the rFVII mutant proteins for either the peptidyl substrate S-2222 (amidolytic assay) or a macromolecular substrate (PT assay) were not statistically different from wild-type rFVII (data not shown) . However, multiple determinations of the affinity of each of the mutant rFVII proteins for immobilized human TF by competitive ELISA (Table 2) indicated that transiently expressed rFVII (K62E) and r.FVII (rabEGFl) bound at least 2.9-fold and 3.3-fold more tightly than did rFVII (WT). Other rFVII EGF-1 mutant proteins were either unchanged or decreased in their affinity for TF. In some experiments, the mutant protein rFVII (A75D) appeared to have enhanced affinity for TF but the data obtained by repeated competitive ELISA binding did not achieve statistical significance.
It should be noted that although mutants (S53N) , (K62E), (P74A), (A75D), or (T83K) , comprising individual amino acid mutations are detailed in this text, however, other modified FVII/FVIIa according to the present invention are also included herein, and may additionally exhibit increased biological activities than the mutant presently detailed herein.
That is to say, the present invention contemplates all mutations at' one or more, or any combination of mutations at positions 53, 62, 74, 75 and 83 of the EGF-1 domain of FVII, wherein the mutations embodied in the present invention exhibit improved biological activity. For example, mutation K62E, or K62T, or A75D, or any other single or multiple point mutation embodied in the present invention showing improved biological activity is embodied herein. Such improved biological activity may comprise an increase in binding affinity for TF, improved anti-coagulant or anti-inflammatory activities.
Where, in a preferred embodiment of the present invention, other FVII EGFl domain mutants displaying
■ increased biological activities where K62 rFVII EGFl mutants . (Accordingly, all rFVII EGFl domain mutants exhibiting improved biological activities, such as increased clotting activity, are embodied in the preset invention. Where, more specifically, mutants -K62D, K62E, K62N, K62Q, and K62T have been shown to exhibit increased clotting" activity, where mutant K62T showed the most improved increase in clotting activity, where clotting activity was increased 2.3-fold compared to the wild- type. Table 2 below summarizes the relative FVII coagulant activity for some rFVII EGFl K62 mutants, wherein all mutants summarized exhibit increased clotting activity with respect to the wild-type FVII.
Table 2 FVII K62 mutant coagulant activity relative to WT
FVII Mutant Coagulant Activity Relative Activity (U/mg)
WT 2085 ± 520 1 . 0
K62D 3025 ± 365 1 . 4
K62E 3490 ± 610 1 . 7
K62N 2800 ± 450 1 . 3
K62Q 2955 ± 540 1 .4
K62T 4835* ± 730 2 . 3
The data show the relative FVII coagulant activity ± SEM (n=ll) of unpurified FVII proteins mutated at the K62 amino acid residue. The asterisk* represents statistical difference (p≤0. 05) as compared to wild-type ' factor VII [FVII (WT) ] .
Purification of rFVII (K62E) and rFVII (A75D) . To confirm the above results, both rFVII (K62E) and rFVII (A75D) were purified to homogeneity from 1-2 liters of HEK293 serum-free conditioned medium. Although both mutant rFVII proteins were ≥ 99% in the zymogen form in unprocessed conditioned medium, initial purification of the mutant proteins via pseudoaffinity chromatography on Q-Sepharose ion-exchange resin resulted in partial activation of mutant rFVII to the rFVIIa form. In order to facilitate comparison of the various rFVII molecules, autoactivation ' of both rFVII (K62E) and rFVII (A75D) to their activated forms was allowed to occur by purposely omitting benzamidine from the column chromatography buffers. The purified rFVIIa EGF-1 mutant proteins were compared to commercially available plasma-derived FVIIa, rFVIIa synthesized in BHK cells and rFVIIa synthesized in HEK293 cells. Analysis by SDS-PAGE and coomassie blue staining (Fig.3) revealed that all FVII preparations were essentially fully activated to FVIIa. A high molecular weight protein contaminant of wild-type rFVIIa (Genentech Inc) can be seen in lane 6. All FVIIa preparations exhibited the expected heavy chain at -30 kDa and light chain at -20 kDa. Western blot analysis of the above gel with human FVII-specific polyclonal IgG revealed virtually identical isoforms of the rFVIIa light chain in all preparations.
Functional Analysis of Purified rFVII (K62E) . To confirm and extend the above results rFVII (K62E) was permanently expressed in HEK293 cells and purified to homogeneity from 1-2 liters of HEK293 serum-free conditioned medium. After purification via pseudoaffinity chromatography on Q-Sepharose ion-exchange resin rFVII (K62E) was >95% pure as judged by SDS-PAGE with coomassie blue staining and western blot analysis (data not shown) . Purification of rFVII (K62E) resulted in 10- 20% activation of rFVII (K62E) to rFVIIa (K62E) . As seen in Fig.4 the relative affinity of purified rFVII (K62E) for full-length relipidated TF as assayed by competitive ELISA was 5-fold greater than either human plasma-derived FVII or human rFVII (WT). This result was confirmed independently by surface plasmon resonance experiments (Table 7) The KD of rFVII (K62E) for human sTF was 1.3 nM, i.e. 5-fold lower than rFVII (WT) and greater than 10-fold lower than pdFVII. In addition to its enhanced affinity for TF, rFVII (K62E) exhibited a 1.9 fold increase in coagulant activity (Table 7) as compared to rFVII (WT) . 45
Table 3. A comparison of the biological activity of purified rFVIIa (K62E) and rFVIIa (A75D) with wild-type FVIIa
Figure imgf000046_0001
wt-rFVII purified commercial wild-typ (wt) rFVIIa from Novo Nordisk Inc. wt-FVII2 plasma-derived human FVII from Enzyme Research Labs * affinity increase of binding between rFVII mutant and human TF, as determined by competitive ELISA (as described in [24])
Table 4 Summary of Activity Changes of Unpurified Recombinant FVII mutants .
Figure imgf000047_0001
wt-r VII1 unpurified wild-type (wt) rFVII from our laboratory. wt-FVII2 plasma-derived human FVII from Enzyme Research Labs clotting activity3 (as described in [24] ) clotting activity3 (as described in [24]) amidolytic activity4 (as described in [24]) binding affinity5 of recombinant FVII mutants to full-length, relipidated human TF, relative to wt-rFVII, as determined by competitive ELISA (as described in [24])
Table 5 summarizes the changes in FVII mutant affinities for human TF.
Table 5 Binding of transiently expressed rFVII mutant proteins to TF
Relative Affinity Relative Increase
FVII Mutant for TF (IC5o) In Affinity for TF T 2.0 ± 0.5 1.0
S53N 5.3 ± 2.0 0.4
K62E 0.7 ± 0.2* 2.9
P74A 2.2 ± 1.0 0.9
A75D 1.2 + 0.5 1.7
T83K 1.9 ± 0.2 1.1 rabEGFl 0.6 ± 0.3* 3.3
The data show the normalized competitive ELISA IC50 values (ng FVII/ml) for inhibition of biotinylated plasma FVII binding to relipidated, full-length human TF. Data are the means ± SEM, n ≥ 3. The asterisk * represents p ≤ 0.05 as compared to the mean of FVII (WT) .
48
Table 6 Absolute affinity of purified rFVII (K62E) for sTF determined by surface plasmon resonance
FVII Sample ka X 10' 5- (M_1 s -1) kd X 10" (s -1) KD (nM) rFVII (WT) 4.3 ± 0 .5 3.1 ± 0. 1 7.2 ±
1.1 pdFVII 1.5 4.4 29.0 rFVII (K62E) 26.0 3.4 1.3
Purified rFVII (WT) was from Genentech Inc. Data are the means ± SEM.
Table 7 Coagulant Activity of Purified rFVII (K62E)
Figure imgf000049_0001
Purified rFVII (WT) was from Genentech Inc. Data are the means ± SEM, n = 4. The asterisks** indicate a statistically significant difference between rFVII (K62E) and rFVII (WT) , p ≤ 0. 01 .
DISCUSSION
The first epidermal growth factor-like domain of human coagulation FVII is essential for high-affinity binding to its cell surface receptor TF [14, 19, 26, 27]. In some studies, replacement of the entire human FVII EGFl domain with the homologous rabbit FVII EGFl region resulted in the formation of a chimeric human rFVII (rabEGFl) molecule which was poorly secreted from HEK293 cells (Fig. 2) but, in the unpurified form, exhibited greater than a 3-fold increase in affinity for TF (Table 5) and an approximate 2-fold increase in specific clotting activity with human TF relative to pdFVII (data not shown) . Subsequently, we examined the effects of the 5 amino acid differences between the human and rabbit FVII EGFl domains (Fig.l) in isolation. Transient expression of the rFVII mutants in HEK293 cells revealed that rFVII (K62E) demonstrated a statistically significant increase in affinity for human TF (Table 5) . Permanent expression and purification of the rFVII (K62E) mutant protein confirmed that it possessed approximately 5-fold increased affinity for human TF (Fig. 3, Table 6) and a 1.9-fold elevation in clotting activity (Table 7) relative to human rFVII (WT) . This data confirms and extends the observations of Janson et al [18], our previous results [28] and the results of others [29] who noted significant differences in the affinity and/or activity of human and rabbit FVII for homologous versus non-homologous TF.
Our laboratory has previously analyzed two naturally-occurring mutations of the FVII EGFl domain which affect binding to TF. Both mutants rFVII (N57D) [15] and rFVII (R79Q) [14,30] exhibited a 5-10 fold decrease in
TF binding but the mechanisms of the two defects differed. Amino acid residue R79 of FVII has been shown to form both hydrophobic and hydrogen bonds with TF [19] whereas the mutation FVII (N57D) did not directly alter
FVII contact with TF but caused a mis-folding of the
FVII EGFl domain [15]. rFVII (R79Q) mutant protein bound normally to the EGFl conformation-sensitive monoclonal antibody 231-7 but rFVII (N57D) mutant protein did not
[15]. Notably, the increased affinity of rFVII (K62E) protein for TF is associated with enhanced' binding of rFVII (K62E) protein to monoclonal antibody 231-7 (data not shown but) , suggesting, that the K→E substitution at position 62 has resulted in a conformational change in the rFVII (K62E) EGFl domain. Although K62 is far removed from the FVII-TF interface [19], the K→E substitution potentially affects its neighboring amino acid residues D63, Q64, 169, C70 and F71 all of which either directly contact TF and/or act as ligands for the single Ca+,+ bound within the FVII EGFl domain.
Naturally-occurring mutants of the EGFl domain have not been reported for either FVII or factor IX at the K62/K63 amino acid residue respectively. Furthermore, the C-K-D tripeptide sequence is absolutely conserved in the factor IX EGFl domain whereas FVII EGFl amino acid residue 62 is variously D (chicken) , E (rabbit & bovine) , Q (mouse & rat) and T (zebrafish) [20, 31, 32] .
A number of laboratories have provided evidence for reciprocal allosteric interaction (s) between the EGFl and protease domains of FVII [33-36] . Perturbations of the FVII EGFl domain including monoclonal antibody 231-7 binding [33] and site-directed mutagenesis affecting the high-affinity Ca++ binding site [34] have been shown to either enhance or decrease FVII catalytic activity respectively. We would therefore suggest that the K62→E amino acid substitution enhances rFVII ■ coagulant activity via an allosteric effect on the protease domain [33] . Furthermore, we submit that the K62→E amino acid exchange likely causes an increased affinity for TF by altering either the conformation of the EGFl domain alone or the relative orientation of the neighboring Gla and EGFl domains [33, 34] . Our results are an interesting contrast to the recent data of Persson et al [37, 38] who- have demonstrated that mutagenesis of selected amino acid residues in the protease domain of rFVII can substantially increase the intrinsic activity of rFVII in an essentially TF-independent manner.
Recombinant FVIIa is currently approved for use in Canada in hemophilia A patients with acquired inhibitors to factor VIII. The chemical amounts of rFVIIa required is a minimum of 2-3 bolus injections of 90 ug rFVII/kg body weight [39] due to the competition of patient plasma FVII zymogen with the infused rFVIIa for available TF [40] . Thus rFVIIa currently constitutes the second most costly drug purchased by the Canadian Blood Services, Canada's blood agency. Conversely, chemically inactivated rFVIIa, termed rFVIIai, which exhibits increased affinity for TF in vitro [41] , has been shown to be an effective inhibitor of thrombosis in vivo in a baboon model [8] and to enhance apoptosis of tumor cells in vitro [42-44 ] . Use of human rFVIIa/rFVIIai would be greatly facilitated by the advent of mutants of rFVIIa with either increased enzymatic activity (in hemophilia) or increased affinity for TF (a better competitive inhibitor) in patients with thrombosis and cancer. Accordingly, mutants of the present invention, wherein the preferred mutants of the present .invention exhibit increased affinity for TF, and/or improved biological activity, may be used to enhance hemostasis in both hemophilia patients with circulating inhibitors and patients with thrombocytopenia, and may additionally be used as anti-coagulant-,and/or anti-inflammatory compounds for the treatment and/or prophylaxis of patients with thrombosis, disseminated intravascular coagulation or cancer.
EXAMPLE
Pharmaceutical Preparations and Methods of Use
Compositions effective for modulating the biological activity of FVII/FVIIa in a mammal, and preferably a human, are encompassed in the present invention. A pharmaceutical composition of the present invention may comprise at least one modified factor FVII/FVIIa (mutant FVII/FVIIa) as herein described, or complexes or fragments thereof. According to a preferred embodiment, a pharmaceutical composition of the present invention comprises a modified' form of factor FVII/FVIIa (mutant FVII/FVIIa) having a mutation at residue 62 thereof, such as mutation K62E, . Preferably, a composition of the present invention improves FVII/FVIIa binding of TF and improves blood coagulation. Accordingly, a pharmaceutical composition of the present invention comprises a purified or unpurified protein, peptide, polypeptide, or functional fragment thereof for mutant FVII/FVIIa (K62E) , or any mutant embodied herein having improved biological activity, or a nucleotide sequence or fragment thereof, in a vehicle (vector, cell,, compound, vesicle) capable of providing and/or expressing mutant FVII/FVIIa in, or to', said patient.
The invention provides modulators (e.g., effectors) of FVII/FVIIa activity and their therapeutic administration. These compounds include one or more of the FVII/FVIIa mutants prepared and/or identified by the methods of the invention. A compound that can be used therapeutically also includes a purified polypeptide, immunogenic polypeptide or polypeptide fragment, nucleotide sequence, vector or cell of the present invention. The peptides, polypeptides and other compounds and/or compositions of the invention are administered with a pharmaceutically acceptable carrier (s) (excipient) to form the pharmaceutical composition.
Pharmaceutically acceptable carriers and formulations, e.g., for the compounds of the present invention are known to the skilled artisan and are described in detail in the scientific and patent literature, see e.g., the latest edition of Remington's Pharmaceutical Science, Mack Publishing Company, Easton, Pa. ("Remington's"); Banga; Putney (1998) Nat. Biotechnol. 16:153-157; Patton (1998) Biotechniques 16:141-143; Edwards (1997) Science 276: 1868-1871; Ho, U.S. Pat. No. 5,780,431; Webb, -U.S. Pat. No. 5,770,700; Goulmy, U.S. Pat. No. 5,770,201.
The compounds or compositions of the present invention can be delivered alone or as pharmaceutical compositions by any means known in the art, e.g., .systemically, regionally, or locally; by intraarterial, intrathecal (IT), intravenous (IV), parenteral, intra- pleural cavity, topical, oral, or local administration, as subcutaneous, intra-tracheal (e.g., by aerosol) or transmucosal (e.g., buccal, bladder, vaginal, uterine, rectal, nasal mucosa) . Actual methods for delivering compositions will be known or apparent to those skilled in the art and are described in detail in the scientific and patent literature, see e.g., Remington's.
The pharmaceutical compositions can be administered by any protocol and in a variety of unit dosage forms depending upon the method of administration, and the like.- Dosages for typical peptide and polypeptide pharmaceutical compositions are well known to those of skill in the art. Such dosages are typically advisorial in nature and are adjusted depending on a variety of factors, such as the particular therapeutic context, patient health and the like. The dosage schedule and amounts effective for this use, i.e., the "dosing regimen," will depend upon a variety of factors, including the stage of the disease being treated; timing of co-administration of other agents; the general state of the patient's health; the patient's physical status; age; the pharmaceutical formulation, and the like. The dosage regimen also takes into consideration pharmacokinetics, e.g., the peptide pharmaceutical composition's rate of absorption, bioavailability, metabolism,. clearance, and the like, see, e.g., Remington .
Dosages can be determined empirically, e.g, by abatement or amelioration of symptoms, or by objective criteria, analysis of blood or histopathology specimens, and the like.
Vectors used for therapeutic administration of modified factor FVII/FVIIa mutant-encoding nucleic acids may be viral or nonviral . Viral vectors are usually introduced into a patient as components of a virus. Illustrative viral vectors into which one can incorporate nucleic acids include, for example, adenovirus-based vectors (Cantwell (1996) Blood 88:4676-4683; Ohashi (1997) Proc. Nat ' 1. Acad. Sci USA 94:1287-1292), Epstein- Barr virus-based vectors (Mazda (1997) J. Immunol. Methods 204:143-151), adenovirus-associated virus vectors, Sindbis virus vectors (Strong (1997) Gene Ther. 4: 624-627), herpes simplex virus vectors (Kennedy (1997) Brain 120: 1245-1259) and retroviral vectors (Schubert (1997) Curr. Eye Res. 16:656-662).
Nonviral vectors encoding products useful in gene therapy can be introduced into an animal by means such as lipofection, biolistics, virosomes, liposomes, immunoliposomes, polycation: nucleic acid conjugates, naked DNA injection, artificial virions, agent-enhanced uptake of DNA, ex vivo transduction. Lipofection is described in e.g., U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., Transfectam.TM. and Lipofectin.TM. ) . Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Feigner, WO 91/17424 and WO 91/16024. Naked DNA genetic vaccines are described in, for example, U.S. Pat. No. 5,589,486.
In accordance with another embodiment of the present invention, a method of treating a mammal having a blood condition is provided, such as hemophilia, or thrombocytopenia, or thrombosis associated with disseminated intravascular coagulation (DIC) , or atherosclerosis and cancer. Preferably, a blood condition includes a compromised ability to adequate maintain blood coagulation. A method of treatment as herein provided includes administration of one or more modified form(s) of factor Vll/VIIa in vivo. Preferably, a modified form of factor Vll/VIIa is in the form of a pharmaceutical composition. According to an alternate embodiment of the present invention, a modified form of factor Vll/VIIa is delivered to a mammal in vivo with an expression vector. That is, a modified form of factor Vll/VIIa is expressed in vivo by an expression vector appropriately delivered to a recipient in need of the modified form of factor Vll/VIIa.
All references cited herein are incorporated herein by reference to the same extent as if each individual publication, patent application or issued patent was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.
The embodiment (s) of the invention described above is (are) intended to be exemplary only. The scope of the invention is therefore intended to be limited solely by the scope of the appended claims.
REFERENCES
1. Hagen FS, Gray CL, O'Hara PJ, Grant FJ, Saari GC, Woodbury RG, Hart CE, Insley M, Kisiel W, Kurachi K, Davie EW. Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sc. USA 1986; 83: 2412-2416.
2. Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46 : 103-112.
3. Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem 2002; 277: 18322-18333.
4. Versteeg HH, Peppelenbosch MP, Spek CA. The pleiotrophic effects of tissue factor: a possible role for factor Vila-induced intracellular signalling. - Thromb Haemost 2001; 86: 1353-1359.
5. Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signalling. Thromb Haemost 2003; 1: 1495-1503. 6. Chen J, , Bierhaus A, Schiekofer S, Andrassy M, Chen B, Stern DM, Nawroth PP.. Tissue factor- a receptor involved in the control of cellular properties, including angiogenesis . Thromb Haemost 2001; 86: 334-345.
7. Konigsberg W, Kirchhofer D, Riederer MA, Ne'merson Y. The TF:VIIa complex: clinical significance, structure-function relationships and its role in signalling and metastasis. Thromb Haemost 2001; 86:757-771.
8. Taylor FB Jr, Chang A, Peer G, Li A, Ezban M, Hedner U. Active site inhibited factor VIIa(DEGR Vila) attenuates the coagulant and interleukin-6 and -8 but not tumor necrosis factor responses of the baboon to LDioo Escherichia coli . Blood 1998; 91: 1609-1615.
9. Kelley RF, Yang J, Eigenbrot C, Moran P, Peek M, Lipari M, Kirchhofer D. ' Similar ■ molecular interactions of factor VII and factor Vila with the tissue factor region that allosterically regulates enzyme activity. Biochem 2004; 43: 1223-1229.
10. Presta L, Sims P, Meng YG, Moran P, Bullens S, Bunting S, Schoenfeld J, Lowe D, Lai J, Rancatore P, Iverson M, Lim A, Chisholm.V, Kelley RF, Riederer M, Kirchhofer D. Generation of a humanized, high- affinity anti-tissue factor antibody for use as, a novel therapeutic. Thromb Haemost 2001; 85: 379-
389. ;
11. Yang J, Lee GF, Riederer MA, Kelley RF. Enhancing the anticoagulant potency of soluble tissue factor mutants by increasing their affinity to factor Vila. Thromb Haemost 2002; 87: 450-458.
12. Dennis MS, Eigenbrot C, Skeleton NJ, Ultsch MH, Santell L, Dwyer MA, O'Connell MP, Lazarus RA.-
Peptide exosite inhibitors of factor Vila as anticoagulants. Na ture 2000; 404: 465-470.
13. Maun HR, Eigenbrot C, Lazarus RA. Engineering exosite peptides for complete inhibition of factor
Vila ' using a protease switch with substrate phage. J Biol Chem 2003; 278: 21823- 21830. 14. Chaing S, Clarke BJ, Sridhara S, Chu K, Friedman P, Van Dusen W, Roberts, HR, Blajchman M, Monroe DM, High KA. Severe factor VII deficiency caused by mutations abolishing the cleavage site for activation and altering binding to tissue factor. Blood 1994; 83: 3524-3535.
15. Leonard BL, Chen Q, Blajchman MA, Ofosu FA, Sridhara S, Yang D, Clarke BJ. Factor VII ' deficiency caused by a structural variant N57D of the first epidermal growth factor domain. Blood 1998; 91: 142-148.
16. McVey JH, Boswell E, Mumford AD, Kemball-Cook G, Tuddenham EGD. Factor VII deficiency and the factor VII mutation database. Human Mutation 2001; 17: 3-17.
17. Dickinson CD, Kelly CR, Ruf W. Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor Vila. Proc Natl Acad Sci USA 1996; 93: 14379-14384.
18. Janson TL, Stormorken H, Prydz H. Species specificity of tissue thromboplastin. Haemostasis
1984; 14: 440-444.
19. Banner DW, D'Arcy A, Chene C, Winkler FK, Guha A, Konigsberg WH, Nemerson Y, Kirchhofer D. The crystal structure of the complex of factor Vila with soluble tissue factor. Nature 1996; 380: 41-46.
20. Ruiz S, Sridhara S, Blajchman A, Clarke BJ. Expression and purification of recombinant rabbit factor II. Thromb Res 2000; 98: 203-211.
21. Williamson V, Pyke A, Sridhara, S, Blajchman MA, Clarke BJ. Interspecies exchange mutagenesis of the first epidermal growth factor-like domain of human factor VII. J Thromb Haemost 2003; Suppl 1: abstract PO 559. ,
22. Clarke BJ, Sridhara S. Incomplete gamma carboxylation of human coagulation factor VII: differential effects on tissue factor binding and enzymatic activity. Brit J Haema tol 1996; 93: 445-450.
23. Yan SCB, Razzano P, Chao B, Walls J, Berg D, McClure D, Grinnell B. Characterization and novel purification of recombinant human protein C from three mammalian cell lines. Bio/technology 1990; 8: 655-661. 24. Sridhara S, Chaing S, High KA, Blajchman MA, Clarke BJ. Activation of a recombinant human factor VII structural variant alters its affinity of binding to tissue factor. Amer J Hema tol 1996; 53: 66-71. 25. Kelley RF, Costas KE, O^Connell MP, Lazarus RA. Analysis of the factor Vila binding site on human tissue factor: effects of tissue factor mutations on the kinetics and thermodynamics of binding. Biochem 1995; 34: 10383-10392.
26. Clarke BJ, Ofosu FA, Sridhara S, Bona RD, Rickles FR, Blajchman MA. The first epidermal growth factor domain of human coagulation factor VII is essential for binding to tissue factor. Febs Letts 1992; 298: 206-210. 27. Chang JY, Stafford DW, Straight DL. The roles of factor VII 's structural domains in tissue factor binding. Biochem 1995; 34: 12227-12232.
28. Clarke BJ, Sridhara S, Blajchman MA, Hatton MWC. Inhibition of the rabbit extrinsic pathway of coagulation: A comparison of rabbit and human FVII structural analogues. Can J Cardiol 2003; 18: (Suppl
B) : 202B, abstract 331. 29. Kelley RF, Refino CJ, O'Connell MP, Modi N, Sehl P, Lowe D, Pater C, Bunting S. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. Blood 1991 ; 89: 3219-3227. 30. O'Brien DP, Kemball-Cook G, Hutchinson AM, Martin DMA, Johnson DJD, Byfield PGH, Takamiya 0, Tuddenham EGD, McVey JH. Surface plasmon resonance studies of the interaction between factor VII and tissue factor. Biochem 1994; 33: 14162-14169.
31. Davidson CJ, Tuddenham EG, McVey JH. .450 million years of hemostasis. J Thromb Haemost 2003; 1: 1487-1494. 32. Seetharam S, Murphy K, Atkins C, Feuerstein G. Cloning and expresssion of rat coagulation factor VII. Thromb Res 2003 109: 225-231.
33. Leonard BJN, Clarke B J, Sridhara S, Kelley R, Ofosu FA, Blajchman MA. Activation and active site occupation alter conformation in the region of the first epidermal growth factor-like domain of human
. factor VII. J Biol Chem 2000; 275: 34894-34900. 34. Persson E, Olsen OH, Ostergaard A, Nielsen LS . Ca2+ binding to the first epidermal growth factor-like domain of factor Vila increases amidolytic activity and tissue factor affinity. J Biol Chem 1997; 272: 19919-19924.
35. Jin J, Perera L, Stafford D, Pedersen L. Four loops of the catalytic domain of factor Vila mediate the' effect of the first EGF-like domain substitution on factor' Vila catalytic activity. J MolBiol 2001; 307:1503-1,517. 36. Dickinson CD, Shobe J, Ruf W. Influence of cofactor binding and active site occupancy on the conformation of the macromolecular substrate exosite of factor Vila. J Mol Biol 1998; 277: 959-971. 37. Persson E. Variants of recombinant factor Vila with increased intrinsic activity. Semin Hematol 2004; 41(Suppl 1) : 89-92.
38. Persson E, Kjalke M, Olsen OH. Rational design of coagulation factor Vila variants with substantially increased intrinsic activity. Proc Na tl Acad Sci USA 2001; 98: 13583-13588.
39. Hedner U. Recombinant factor Vila (Novoseven) as a hemostatic agent. Semin Hematol 2001; 38(Suppl 1.2):
43-47.
40. Butenas S, Brummel B, Mann KG. How factor Vila works in hemophilia. J Thromb Haemost 2003; 1: 1158-1160.
41. Sorensen BB, Persson E, Freskgard PO, Kjalke M, Ezban M, Williams T, Rao LVM. Incorporation of an active site inhibitor in factor Vila alters the affinity for TF. J Biol Chem 1997; 272: 11863-11868.
42. Sorensen BB, Rao LV, Tornehave D, Gammeltoft S, Petersen LC. Antiapoptotic effect of coagulation factor Vila. Blood 2003; 102: 1708-171-5. 43. Jiang X, Bailly MA, Panetti TS, Cappello M, Konigsberg WH,' Bromberg ME. Formation of tissue factor-factor Xa complex promotes cellular signalling and migration of- human breast cancer cells. J Thomb Haemost 2003; 2: 93-101.
44. Versteeg HH, Spek CA, Richel DJ, Peppelenbosch MP. Coagulation factors Vila and Xa inhibit apoptosis and anoikis. Oncogene 2004; 23: 410-417. 45. Butenas S, Brummel B, Mann K. How factor Vila works in hemophilia. J Thromb Haemost 2003; 1:1158-1160. THIS REF REPLACES VANT VEER. 6. Roberge M, Peek M, Kirchhofer D, Dennis MS, Lazarus RA. Fusion of two distinct peptide exosite inhibitors of factor Vila. Biochem J 2002;263: 387- 393.

Claims

I /WE CLAIM :
1. A modified factor Vll/VIIa (mutant FVII/FVIIa) or functional fragment thereof, comprising one or more mutation(s), wherein said mutation(s) is/are in the epidermal growth factor-like (EGF-1) domain.
2. A modified FVII/FVIIa according to claim 1, wherein wherein said mutation (s) is/are at one, more than one, or all amino acid residues at positions 53, 62, 74, 75, 83, or any combination thereof, wherein said mutation (s) may- be to any amino acid . residue that confers enhanced biological activity of said FVII/FVIIa.
3. ' A modified FVII/FVIIa according to claim 1, wherein said mutant FVII/FVIIa comprises one, more than one or all mutations selected from (S53N) , (K62E) ,
(K62D) , (K62N), (K62Q) , (K62T) , (P74A), (A75D) , or
(T83K) , or any combination thereof.
4. A modified FVII/FVIIa according to claim 1, wherein said mutant FVII/FVIIa comprises mutation (K62E) or mutation (K62T) .
5. A polypeptide, immunogenic polypeptide, or polypeptide fragment comprising a modified FVII/FVIIa according to any one of claims 1 to 4.
6. A modified FVII/FVIIa according to any one of claims 1 to 4, .wherein said mutation .enhances enzymatic activity and/or affinity for TF.
7. An nucleotide comprising a sequence that encodes a polypeptide, immunogenic polypeptide, or polypeptide fragment according to claim 5.
8. A recombinant nucleotide, or isolated nucleotide sequences encoding modified FVII/FVIIa according to any one of claims 1 to 4 or any degenerate variant thereof.
9. A nucleotide sequence comprising a sequence that encodes a modified FVII/FVIIa sequence, wherein said sequence specifically hybridizes to a sequence selected from SEQ ID NO: 21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO: 30 or any degenerate variant thereof.
10. A nucleotide sequence comprising a sequence that encodes a nucleic acid sequence that encodes any modified FVII/FVIIa according to any one of claims 1 to 4.
11. A nucleotide sequence comprising any one of SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ
ID NO: 5,' SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO: 9, SEQ ID NO: 10 or any degenerate variant thereof.
12. A nucleotide sequence comprising a sequence that encodes a polypeptide comprising the Rabbit amino acid sequence of Fig.l, or an amino acid sequence comprising one, more than one or all mutations specified therein, or any combinations thereof.
13. A nucleotide sequence comprising a sequence that encodes a polypeptide according to claim 5.
14. A polypeptide comprising the amino acid sequence of any modified FVII/FVIIa according to any one of claims 1 to 4.
15. A polypeptide comprising the amino acid any one of SEQ ID NO:ll, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID N0:15, SEQ ID NO:16, SEQ ID NO:17, .SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20.
16. A vector comprising a nucleotide sequence encoding a modified FVII/FVIIa according to any one of claims 1 to 4, 11, or 44.
17. A vector comprising a nucleotide sequence according to claim 11. ι
18. A vector according to claim 16 or 17, wherein said vector may be an expression vector or- a cloning vector.
19. A vector according to claim 18, wherein said expression vector is pCMV5.
20. A vector- according to claim 18, wherein said cloning vector is pUC19.
21. A culture cell or cell line transfected with a vector according to claim 16 or 17, or a progeny of said cell, wherein said culture cell or cell line expresses the modified FVII/FVIIa.
22. A culture cell or cell line according to claim 21, wherein said cell or cell line HEK293, CHO or BHK cells or any related cell or progeny thereof.
23. A culture cell or cell line that permanently expresses a mutant nucleotide sequence' of a mutant FVII/FVII according to any one of claims 1 to 4, 11 or 44.
24. A culture cell or cell line transfected with a vector according to claim 19, co-transfected with selection plasmid pSV2neo.
25. A culture cell or cell line according to claim 24, wherein said cell or cell line is HEK293, CHO or BHK or equivalent cell or progeny thereof.
26. A HEK293 culture cell or cell line that expresses a factor according to any one of claims 1 to 4, 11 or 44.
27'. A HEK293 culture cell or cell line that expresses a modified FVII (K62E) , FVII(K62T) or FVII (A75D) , or any other mutant according to claims 1 to 4, 11 or 44.
28. A method for expressing a modified FVII/VIIa factor in a cell, said method comprising:
a) providing an expression vector encoding said factor;
b) introducing the vector into said cell; and
c) maintaining the cell under conditions permitting expression of said factor in the cell .
29. A method of claim 28, wherein said modified factor Vll/VIIa is according to any one of claims 1 to 4.
30. A method of claim 28, wherein said expression vector is pCMV5.
31. A method of claim 28, wherein said cell is HEK293.
32. The method of claim 28 wherein said protein is expressed in a cell in vivo or in vitro.
33. A pharmaceutical composition comprising a modified FVII/FVIIa, or functional fragment thereof, according to any one of claims 1 to 4, 15, 45 or complexes of said modified FVII/FVIIa and a pharmaceutically accepted carrier.
34. A method for treating a patient with a blood condition, comprising introducing into the patient an expression vector encoding a modified factor VII protein, or functional fragment thereof, according to any one of claims 1 to 4, 15, 45 or a complex thereof, such L that an amount of said protein is effective to improve coagulation.
35. A method for treating a patient with a blood condition, said method comprising administering a pharmaceutical effective amount of a composition according to claim 33. '
36. A method for treating a patient according to claim 35, wherein said modified FVII/FVIIa, or functional fragment thereof, may be complexed to another molecule, or may be encapsulated in an pharmaceutically acceptable vehicle.
37. A modified factor Vll/VIIa (mutant FVII/FVIIa) comprising any one or more mutation (s) in the epidermal growth factor-like (EGF-1) domain, wherein said mutation (s) confer (s) enhanced biological activity.
38. A modified human factor Vll/VIIa (mutant human FVII/FVIIa) comprising any one or more mutation (s). in the epidermal growth factor-like (EGF-1) domain, wherein said mutation (s) confer (s) enhanced biological activity.
39. A modified FVII/FVIIa according to any one of claims 1 to 35, wherein said mutation (s) confers enhanced biological activity of FVII/FVIIa to positively improve blood coagulation.
40. A modified factor Vll/VIIa according to any one of claims 2, 37, 38 or 39, wherein said biological activity comprises binding affinity of said modified FVII/FVIIa to bind TF.
41. A modified FVII/FVIIa according to any one of claims 1 to 35, wherein said modified FVII/FVIIa is a modified human FVII/FVIIa.
42. A method according to claim 34 or 35, wherein said condition comprises any blood disorder, for treating a patient with a blood condition, such as hemophilia, or thrombocytopenia, or thrombosis associated with disseminated intravascular coagulation (DIC), or atherosclerosis and cancer.
43. A method according to claim 42, wherein said modified FVII/FVIIa is a modified human FVII/VIIa according to any one of claims 1 to 27.
44. A modified FVII/FVIIa nucleotide sequence, whrein the EGFl domain comprises any one of SEQ ID N0:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID N0:4, or SEQ ID NO:5, SEQ ID NO: 6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO: 9, SEQ ID NO: 10 or any degenerate variant thereof.
45. A modified FVII/FVIIa protein, wherein the EGFl domain comprises an amino acid comprising any one of SEQ ID NO:ll, SEQ ID NO:12, SEQ ID NO:13, SEQ ID N0:14, or SEQ ID N0:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID N0:19, SEQ ID NO:20, or any functional fragment thereof.
PCT/CA2004/000826 2003-06-05 2004-06-03 Mutants of the factor vii epidermal growth factor domain WO2004108763A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002528239A CA2528239A1 (en) 2003-06-05 2004-06-03 Mutants of the factor vii epidermal growth factor domain
EP04735858A EP1636358A2 (en) 2003-06-05 2004-06-03 Mutants of the factor vii epidermal growth factor domain
US11/294,670 US20060234935A1 (en) 2003-06-05 2005-12-05 Mutants of the factor VII epidermal growth factor domain
US11/636,030 US20070207960A1 (en) 2003-06-05 2006-12-08 Mutants of the factor VII epidermal growth factor domain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47590503P 2003-06-05 2003-06-05
US60/475,905 2003-06-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/294,670 Continuation US20060234935A1 (en) 2003-06-05 2005-12-05 Mutants of the factor VII epidermal growth factor domain

Publications (2)

Publication Number Publication Date
WO2004108763A2 true WO2004108763A2 (en) 2004-12-16
WO2004108763A3 WO2004108763A3 (en) 2005-02-17

Family

ID=33511728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2004/000826 WO2004108763A2 (en) 2003-06-05 2004-06-03 Mutants of the factor vii epidermal growth factor domain

Country Status (4)

Country Link
US (1) US20060234935A1 (en)
EP (1) EP1636358A2 (en)
CA (1) CA2528239A1 (en)
WO (1) WO2004108763A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
WO2007006808A1 (en) 2005-07-13 2007-01-18 Novo Nordisk Health Care Ag Host cell protein knock-out cells for production of therapeutic proteins
WO2007026021A1 (en) 2005-09-01 2007-03-08 Novo Nordisk Health Care Ag Hydrophobic interaction chromatography purification of factor vii polypeptides
WO2008025856A2 (en) 2006-09-01 2008-03-06 Novo Nordisk Health Care Ag Modified glycoproteins
EP2316930A1 (en) 2005-09-14 2011-05-04 Novo Nordisk Health Care AG Human coagulation factor VII polypeptides
EP2481797A1 (en) 2007-04-13 2012-08-01 Catalyst Biosciences, Inc. Modified factor VII polypeptides and uses thereof
EP2679678A1 (en) 2008-04-11 2014-01-01 Catalyst Biosciences, Inc. Factor VII polypeptides that are modified and uses thereof
US8828939B2 (en) 2004-08-17 2014-09-09 Csl Behring Gmbh Modified vitamin K dependent polypeptides
WO2014190860A1 (en) * 2013-05-29 2014-12-04 四川大学 Human source egf structural domain protein and application of same
JP2016521685A (en) * 2013-05-29 2016-07-25 チョントゥー ソースバイオ リミテッド ライアビリティ カンパニー Human coagulation factor light chain protein and use thereof
US11266724B2 (en) 2019-08-15 2022-03-08 Catalyst Biosciences, Inc. Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2445513B1 (en) 2009-06-25 2014-08-27 The University of North Carolina At Chapel Hill Chimeric factor vii molecules
CN116143929B (en) * 2023-02-03 2023-08-01 北京基科晟斯医药科技有限公司 Antibody against recombinant human coagulation factor VIIa-Fc fusion protein and application thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BROTHERS ALEX B ET AL: "Complete nucleotide sequence of the cDNA encoding rabbit coagulation factor VII" THROMBOSIS RESEARCH, vol. 69, no. 2, 1993, pages 231-238, XP9041224 ISSN: 0049-3848 *
CLARKE B.: "Interspecies exchange mutagenesis of the first growth factor-like domain of human factor VII" J. THROMBOSIS AND HAEMOSTASIS, vol. 1, 2003, page ABSTRACT NUMBER P0559, XP001204193 SUPPLEMENT 1 JULY *
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; June 1998 (1998-06), KAVLIE ANITA ET AL: "Characterization of a factor VII molecule carrying a mutation in the second epidermal growth factor-like domain" XP002309720 Database accession no. PREV199800347106 & THROMBOSIS AND HAEMOSTASIS, vol. 79, no. 6, June 1998 (1998-06), pages 1136-1143, ISSN: 0340-6245 *
KAZAMA Y ET AL: "Evidence that an Arg-79 fwdarw Gln substitution in human factor VII is not associated with a reduction in coagulant activity" BLOOD COAGULATION AND FIBRINOLYSIS, vol. 3, no. 6, 1992, pages 697-702, XP009041242 ISSN: 0957-5235 *
PERSSON E ET AL: "Ca2+ in the first epidermal growth factor-like domain of activated factor VII" BLOOD COAGULATION AND FIBRINOLYSIS, vol. 9, no. SUPPL. 1, March 1998 (1998-03), pages S79-S81, XP009041243 & 4TH SYMPOSIUM ON NEW ASPECTS OF HAEMOPHILIA TREATMENT; COPENHAGEN, DENMARK; SEPTEMBER 19-20, 1997 ISSN: 0957-5235 *
SRIDHARA SAMPATH ET AL: "Activation of a recombinant human factor VII structural analogue alters its affinity of binding to tissue factor" AMERICAN JOURNAL OF HEMATOLOGY, vol. 53, no. 2, 1996, pages 66-71, XP009041225 ISSN: 0361-8609 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828939B2 (en) 2004-08-17 2014-09-09 Csl Behring Gmbh Modified vitamin K dependent polypeptides
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
EP2360170A2 (en) 2005-06-17 2011-08-24 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine
WO2007006808A1 (en) 2005-07-13 2007-01-18 Novo Nordisk Health Care Ag Host cell protein knock-out cells for production of therapeutic proteins
WO2007026021A1 (en) 2005-09-01 2007-03-08 Novo Nordisk Health Care Ag Hydrophobic interaction chromatography purification of factor vii polypeptides
EP2316930A1 (en) 2005-09-14 2011-05-04 Novo Nordisk Health Care AG Human coagulation factor VII polypeptides
WO2008025856A2 (en) 2006-09-01 2008-03-06 Novo Nordisk Health Care Ag Modified glycoproteins
EP2481797A1 (en) 2007-04-13 2012-08-01 Catalyst Biosciences, Inc. Modified factor VII polypeptides and uses thereof
EP2679678A1 (en) 2008-04-11 2014-01-01 Catalyst Biosciences, Inc. Factor VII polypeptides that are modified and uses thereof
EP2687596A2 (en) 2008-04-11 2014-01-22 Catalyst Biosciences, Inc. Factor VII polypeptides that are modified and uses thereof
EP3064580A1 (en) 2008-04-11 2016-09-07 Catalyst Biosciences, Inc. Factor vii polypeptides that are modified and uses thereof
US11203749B2 (en) 2008-04-11 2021-12-21 Catalyst Biosciences, Inc. Factor VII polypeptides that are modified and uses thereof
US10160961B2 (en) 2008-04-11 2018-12-25 Catalyst Biosciences, Inc. Factor VII polypeptides that are modified and uses thereof
WO2014190860A1 (en) * 2013-05-29 2014-12-04 四川大学 Human source egf structural domain protein and application of same
JP2016521685A (en) * 2013-05-29 2016-07-25 チョントゥー ソースバイオ リミテッド ライアビリティ カンパニー Human coagulation factor light chain protein and use thereof
US9833497B2 (en) 2013-05-29 2017-12-05 Chengdu Sourcebio Limited-Liability Company Human originated EGF domain proteins and use of the same
CN104211799B (en) * 2013-05-29 2017-12-26 成都渊源生物科技有限公司 Human Epidermal growth factor domain protein and its application
JP2016520599A (en) * 2013-05-29 2016-07-14 チョントゥー ソースバイオ リミテッド ライアビリティ カンパニー Human origin EGF domain protein and use thereof
CN105683216A (en) * 2013-05-29 2016-06-15 成都渊源生物科技有限公司 Human source EGF structural domain protein and application of same
US11266724B2 (en) 2019-08-15 2022-03-08 Catalyst Biosciences, Inc. Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

Also Published As

Publication number Publication date
CA2528239A1 (en) 2004-12-16
WO2004108763A3 (en) 2005-02-17
EP1636358A2 (en) 2006-03-22
US20060234935A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
US20060234935A1 (en) Mutants of the factor VII epidermal growth factor domain
US8828939B2 (en) Modified vitamin K dependent polypeptides
US9856467B2 (en) Modified factor X polypeptides and uses thereof
EP1891091B1 (en) Coagulation factor x polypeptides with modified activation properties
JP4847856B2 (en) Variants of FVII and FVIIa
JP4709395B2 (en) Modified vitamin K-dependent polypeptide
EP1991255B1 (en) Coagulation factor x polypeptides with modified activation properties
EP2481797A1 (en) Modified factor VII polypeptides and uses thereof
BRPI0911060B1 (en) Factor vii polypeptides that are modified and uses thereof
JP2012095641A6 (en) Variants of FVII and FVIIa
JP2009533364A (en) Methods for increasing in vivo recovery of therapeutic polypeptides
US20070207960A1 (en) Mutants of the factor VII epidermal growth factor domain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2528239

Country of ref document: CA

Ref document number: 11294670

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004735858

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004735858

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWP Wipo information: published in national office

Ref document number: 11294670

Country of ref document: US